<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Sedative-analgesia in ventilated adults: Management strategies, agent selection, monitoring, and withdrawal
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Sedative-analgesia in ventilated adults: Management strategies, agent selection, monitoring, and withdrawal
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Sedative-analgesia in ventilated adults: Management strategies, agent selection, monitoring, and withdrawal
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Barry Fuchs, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Cassandra Bellamy, PharmD, BCPS
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Polly E Parsons, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Michael F O'Connor, MD, FCCM
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Geraldine Finlay, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Dec 19, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Distress generally presents as agitation. It is common among critically ill patients, especially those who are intubated [
         <a href="#rid1">
          1
         </a>
         ]. Distress needs to be treated for patient comfort and to decrease sympathetic tone, which may have untoward physiologic effects [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
         The management of distress in critically ill adults, including the initiation, maintenance, and withdrawal of pharmacologic sedation, is reviewed here. The mechanism, pharmacokinetics, and adverse effects of common sedative-analgesic medications, the treatment of pain, and the use of neuromuscular blocking agents in critically ill patients are discussed elsewhere.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/1616.html" rel="external">
          "Sedative-analgesia in ventilated adults: Medication properties, dose regimens, and adverse effects"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/2888.html" rel="external">
          "Pain control in the critically ill adult patient"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/1590.html" rel="external">
          "Neuromuscular blocking agents in critically ill patients: Use, agent selection, administration, and adverse effects"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          INITIAL ASSESSMENT AND TREATMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The cornerstone of treating agitation involves treating the underlying critical illness and reason for distress (eg, pain anxiety, delirium) and use of nonpharmacologic interventions.
        </p>
        <p class="headingAnchor" id="H4030428011">
         <span class="h2">
          Treat underlying critical illness
         </span>
         <span class="headingEndMark">
          —
         </span>
         Several conditions and their associated symptoms can lead to distress, including, but not limited to, drug withdrawal, infection, dyspnea, hypoxemia, and shock. Strategies to alleviate distress due to the underlying illness include simple maneuvers, such as adjusting ventilator settings for dyssynchrony and/or derangements in gas exchange, antipyretics for high fever, hemodynamic support with fluids and/or vasopressors for shock, antimicrobials for suspected infection, and/or heart rate control for arrythmias. Evaluation and management of respiratory distress in mechanically ventilated patients are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1633.html" rel="external">
          "Assessment of respiratory distress in the mechanically ventilated patient"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1074170727">
         <span class="h2">
          Identify the etiology of distress
         </span>
         <span class="headingEndMark">
          —
         </span>
         As an initial strategy, we identify the cause of the distress so that targeted treatment can be administered. Not uncommonly, there may be more than one reason for distress, necessitating combination therapy. (See
         <a class="local">
          'Combination therapy'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H301119079">
         <span class="h3">
          General history and examination
         </span>
         <span class="headingEndMark">
          —
         </span>
         The primary causes of distress in critically ill patients include anxiety or fear, pain, dyspnea, and delirium. These etiologies can be assessed more readily in awake and nonintubated patients, with assessment being more challenging in intubated and/or sedated patients. Thus, in a newly intubated patient, we often use clinical judgement based upon the patient's previous history or reason for intubation to make this assessment. We ask simple "yes or no" questions, such as the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Are you in pain or discomfort?
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Are you afraid?
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Do you feel anxious?
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Do you feel short of breath?
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Are you thirsty?
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Do you know where you are?
        </p>
        <p>
        </p>
        <p>
         We may also use other cues, such as facial expressions (eg, grimacing on palpation), vital signs, and response to analgo-sedative therapy, to assess the presence and severity of symptoms.
        </p>
        <p>
         When patients are unable to report their symptoms, validated tools for pain and delirium can supplement clinical history and examination for objective assessment. (See
         <a class="local">
          'Assessment anxiety, pain, delirium'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H2484806184">
         <span class="h3">
          Assessment anxiety, pain, delirium
         </span>
         <span class="headingEndMark">
          —
         </span>
         We also specifically evaluate for anxiety, pain, or delirium, which facilitates directed therapy.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Anxiety
         </strong>
         – Reports suggest a wide range of intensive care unit (ICU) patients experience anxiety (12 to 80 percent) [
         <a href="#rid3">
          3,4
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Source – Fear of suffering or death, loss of control, and frustration due to the inability to effectively communicate are typical causes of anxiety in critically ill patients.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Manifestations – Symptoms and signs include headache, nausea, insomnia, dyspnea, palpitations, dizziness, dry mouth, chest pain, diaphoresis, hyperventilation, pallor, tachycardia, tremulousness, and/or hypervigilance.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Assessment tools – Self report and clinical evaluation are the most widely used methods for evaluating anxiety. While patient and provider assessment tools for anxiety have been reported in the literature including the Visual Analog Scale-Anxiety (VAS-A) and the Faces Anxiety Scale [
         <a href="#rid5">
          5
         </a>
         ], they are not commonly used in routine clinical practice.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pain
         </strong>
         – Pain is likely underreported in ICU patients, and a significant proportion of ICU survivors report experiencing moderate to severe pain during ICU care [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Source – Pain can be due to routine patient care (eg, suctioning, repositioning, physical therapy), immobility, trauma, surgery, endotracheal tubes, and other monitoring devices.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Manifestations – Patients may report pain or have evidence of pain, including grimacing, withdrawal, combativeness, diaphoresis, hyperventilation, and/or tachycardia.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Assessment tools – While self-reporting is preferred over behavioral pain scales, we use unidimensional scales in patients who can communicate or multidimensional scales in nonverbal patients.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Patients who can communicate – The unidimensional scales can be quickly and easily applied in the ICU if the patient is communicative. As an example, the numeric pain rating scale is a 0 to 10-point scale on which 10 represents the worst pain and 0 is no pain  (
         <a class="graphic graphic_figure graphicRef72905" href="/z/d/graphic/72905.html" rel="external">
          figure 1
         </a>
         ); patients choose the number that best describes their pain. Other alternatives include the verbal rating scale or visual analogue scale.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Nonverbal patients – Multidimensional scales are more complex than unidimensional scales and take longer to administer but can be used in nonverbal patients, which is common in the ICU. Most commonly used and recommended by guideline groups are the Behavioral Pain Scale (BPS)  (
         <a class="graphic graphic_table graphicRef103690" href="/z/d/graphic/103690.html" rel="external">
          table 1
         </a>
         ) and the Critical Care Pain Observation Tool (CPOT)  (
         <a class="graphic graphic_table graphicRef103691" href="/z/d/graphic/103691.html" rel="external">
          table 2
         </a>
         ) since they are simple, valid, and reliable in critically ill patients [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         A more detailed assessment of pain in critically ill patients is provided separately. (See
         <a class="medical medical_review" href="/z/d/html/2888.html" rel="external">
          "Pain control in the critically ill adult patient", section on 'Assessment for pain'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Delirium
         </strong>
         – Delirium occurs in up to 80 percent of ICU patients. It is frequently unrecognized in older individuals and in patients who have hypoactive delirium [
         <a href="#rid8">
          8,9
         </a>
         ]. Hyperactive delirium is more readily apparent (eg, delirium due to drug or alcohol withdrawal) [
         <a href="#rid10">
          10
         </a>
         ]. Delirium is a risk factor for prolonged hospitalization and mortality in critically ill patients [
         <a href="#rid11">
          11-13
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Risk factors – Risk factors for delirium include electrolyte imbalances (hypocalcemia, hyponatremia), hyperamylasemia, hyperglycemia, azotemia, hepatic disease (hyperbilirubinemia, elevated hepatic enzymes), infections, drug or alcohol withdrawal, malnutrition, cancer, cerebrovascular disease, cardiopulmonary disease, advanced age, and some medications (eg, benzodiazepines, corticosteroids, antihistamines, beta blockers, antiarrhythmics, digitalis glycosides,
         <a class="drug drug_general" data-topicid="8983" href="/z/d/drug information/8983.html" rel="external">
          atropine
         </a>
         ) [
         <a href="#rid14">
          14
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Manifestations – In the acute phase, delirious patients have impaired short-term memory, abnormal perception, and intermittent disorientation, which is usually worse at night.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Assessment tools – Many scales and diagnostic instruments have been developed to identify and evaluate delirium, but most exclude critically ill patients due to difficulty communicating with them. Nonetheless, society guidelines promote the regular assessment of critically ill patients with a delirium assessment tool, understanding that the level of arousal may affect accurate assessment. This includes the confusion assessment method for the intensive care unit (CAM-ICU) scale (the original CAM table  (
         <a class="graphic graphic_table graphicRef69489" href="/z/d/graphic/69489.html" rel="external">
          table 3
         </a>
         ) was modified for ICU patients) [
         <a href="#rid15">
          15
         </a>
         ] and the Intensive Care Delirium Screening Checklist (ICDSC) [
         <a href="#rid16">
          16
         </a>
         ]. Both scales assess patients for acute mental status changes or fluctuating mental status changes, inattention, disorganized thinking, and/or an altered level of consciousness. Both scales can identify new or persistent delirium, but neither quantify the severity of the delirium. (See
         <a class="medical medical_review" href="/z/d/html/4824.html" rel="external">
          "Diagnosis of delirium and confusional states", section on 'Recognizing the disorder'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Further details on the evaluation of delirium are provided separately. (See
         <a class="medical medical_review" href="/z/d/html/4824.html" rel="external">
          "Diagnosis of delirium and confusional states", section on 'Evaluation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h2">
          Nonpharmacologic approaches
         </span>
         <span class="headingEndMark">
          —
         </span>
         We apply nonpharmacologic strategies prior to or in combination with pharmacologic treatment. Combination therapy is common since the cause of the distress is rarely quickly reversible. (See
         <a class="local">
          'Initiating sedative-analgesics'
         </a>
         below and
         <a class="local">
          'Combination therapy'
         </a>
         below.)
        </p>
        <p>
         Initial nonpharmacologic strategies include reassurance and frequent communication with the patient [
         <a href="#rid17">
          17
         </a>
         ]. Over the course of the ICU stay, it also includes regular caregiver visits, establishment of normal sleep cycles, correction of sensory deficits, noise reduction, minimizing use of lines and tubes, relaxation therapy (eg, massage) and cognitive-behavioral therapies (eg, music), physical and occupational therapies, and caregiver interaction [
         <a href="#rid18">
          18-25
         </a>
         ].
        </p>
        <p>
         Even when both nonpharmacologic and pharmacologic interventions are employed, use of physical restraints may be required if the perceived risk of self or caregiver harm cannot be minimized. Restraints should never be the sole method employed for managing patients in the ICU, and when employed, every effort should be made to discontinue them as soon as possible. Further discussion is provided separately. (See
         <a class="medical medical_review" href="/z/d/html/4823.html" rel="external">
          "Delirium and acute confusional states: Prevention, treatment, and prognosis", section on 'Nonpharmacologic interventions'
         </a>
         .)
        </p>
        <p>
         Data to support nonpharmacologic interventions include the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Verbal reassurance – One trial randomly assigned 140 mechanically ventilated patients to receive either a strategy of continuous verbal comforting and reassurance without sedation ("no sedation") or continuous sedation with daily interruption of sedatives [
         <a href="#rid20">
          20
         </a>
         ]. For the no sedation group, only when nonpharmacologic interventions failed were patients treated with a continuous sedative infusion with daily interruption. Patients managed with a strategy of no sedation had more ventilator-free days, decreased length of ICU and hospital stay, and decreased incidence of delirium. There was no difference in posttraumatic stress disorder, quality of life, depression, or recall of the ICU experience in survivors approximately two years after randomization [
         <a href="#rid21">
          21
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Music therapy – Another randomized trial of 373 mechanically ventilated patients reported that patient-directed self-initiated music therapy (PDM) with patient-preferred selections tailored by a music therapist resulted in a reduction in the visual analog scale for anxiety when compared with usual care or noise-cancelling headphones (52 versus 33) [
         <a href="#rid22">
          22
         </a>
         ]. PDM also reduced sedation intensity (sedation intensity score 4.4 versus 2.8) and frequency (5 versus 3 doses of study-approved sedative). These findings were confirmed in a meta-analysis of 14 trials examining the impact of music in mechanically ventilated patients [
         <a href="#rid23">
          23
         </a>
         ]. Reductions in patient distress has also been reported in those receiving noninvasive ventilation [
         <a href="#rid24">
          24
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         High quality sleep – Although many ICUs implement programs to promote high quality sleep (eg, limiting noise and dimming the lights at night), supporting data are lacking. Disordered sleep in critically ill patients is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1628.html" rel="external">
          "Clinical and physiologic complications of mechanical ventilation: Overview", section on 'Disordered sleep'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h1">
          INITIATING SEDATIVE-ANALGESICS
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients in whom treatment of the underlying critical illness and nonpharmacologic strategies have failed to achieve an appropriate level of sedation (eg, calm, cooperative), pharmacologic agents should be administered. This approach reduces the risk of acute and chronic physical and emotional harm, if distress is treated adequately. Once sedative agents are selected and initiated, the dose and/or frequency are titrated to a set target. (See
         <a class="local">
          'Selection of agent(s)'
         </a>
         below and
         <a class="local">
          'Set sedation-analgesia targets (scoring systems)'
         </a>
         below.)
        </p>
        <p>
         For the most part, the administration of sedative-analgesic medications should be based on observed agitation and not on anticipated distress (unless the patient is on neuromuscular blockers [NMB]). This reduces the risk of over sedation, which can prolong length of stay and duration of mechanical ventilation. (See
         <a class="local">
          'Avoiding oversedation'
         </a>
         below.)
        </p>
        <p>
         Patients undergoing neuromuscular blockade should empirically receive pharmacologic sedation and analgesia since neuromuscular paralysis without sedation or adequate pain control is an extremely frightening and unpleasant sensation. Additionally, assessing and treating underlying delirium, pain, or anxiety is impossible in paralyzed patients. Indications for neuromuscular blockade in critically ill patients are discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/1590.html" rel="external">
          "Neuromuscular blocking agents in critically ill patients: Use, agent selection, administration, and adverse effects"
         </a>
         .)
        </p>
        <p>
         Sedative-analgesic medications that are commonly used in the intensive care unit (ICU) include opioid analgesics (eg,
         <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">
          fentanyl
         </a>
         ,
         <a class="drug drug_general" data-topicid="8538" href="/z/d/drug information/8538.html" rel="external">
          hydromorphone
         </a>
         ,
         <a class="drug drug_general" data-topicid="9788" href="/z/d/drug information/9788.html" rel="external">
          morphine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9854" href="/z/d/drug information/9854.html" rel="external">
          remifentanil
         </a>
         ,
         <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">
          methadone
         </a>
         ), nonopioid analgesics (eg,
         <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">
          acetaminophen
         </a>
         , nonsteroidal anti-inflammatory drugs),
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         ,
         <a class="drug drug_general" data-topicid="8897" href="/z/d/drug information/8897.html" rel="external">
          dexmedetomidine
         </a>
         , benzodiazepines (eg,
         <a class="drug drug_general" data-topicid="9345" href="/z/d/drug information/9345.html" rel="external">
          diazepam
         </a>
         ,
         <a class="drug drug_general" data-topicid="9573" href="/z/d/drug information/9573.html" rel="external">
          lorazepam
         </a>
         ,
         <a class="drug drug_general" data-topicid="9650" href="/z/d/drug information/9650.html" rel="external">
          midazolam
         </a>
         ), and antipsychotics (eg,
         <a class="drug drug_general" data-topicid="8516" href="/z/d/drug information/8516.html" rel="external">
          haloperidol
         </a>
         ,
         <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">
          quetiapine
         </a>
         ,
         <a class="drug drug_general" data-topicid="10040" href="/z/d/drug information/10040.html" rel="external">
          ziprasidone
         </a>
         ). Other less commonly used agents include barbiturates and
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          ketamine
         </a>
         [
         <a href="#rid10">
          10,26
         </a>
         ]. All these agents differ in their amount of anxiolysis, analgesia, amnesia, and hypnosis  (
         <a class="graphic graphic_table graphicRef51282" href="/z/d/graphic/51282.html" rel="external">
          table 4
         </a>
         ). Their mechanisms, properties, dosage regimens, and potential adverse effects are listed on the table  (
         <a class="graphic graphic_table graphicRef79667" href="/z/d/graphic/79667.html" rel="external">
          table 5
         </a>
         ) and reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/1616.html" rel="external">
          "Sedative-analgesia in ventilated adults: Medication properties, dose regimens, and adverse effects"
         </a>
         .)
        </p>
        <p>
         Our approach, for the most part, is consistent with The Society of Critical Care Medicine (SCCM) guidelines and Intensive Care Medicine Rapid Practice Guideline (ICM-RPG) [
         <a href="#rid7">
          7,27
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h2">
          Selection of agent(s)
         </span>
         <span class="headingEndMark">
          —
         </span>
         Selection of agent(s) must be individualized since no sedative-analgesic agent is sufficiently superior to other agents to warrant its use in all clinical situations. In practice, observing the response to a specific medication may also help choose an effective agent.
        </p>
        <p>
         When selecting agents, the following applies:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         We select an agent that targets the etiology of the distress – (See
         <a class="local">
          'Target etiology of the distress'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         We then identify any modifying variables that may influence that choice (ie, pharmacologic and nonpharmacologic factors, such as potential interactions with other drugs and clinical status of the patient) – (See
         <a class="local">
          'Modifying variables'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In most cases, more than one agent is needed (eg, anxiolytic/sedative and analgesic agents) – (See
         <a class="local">
          'Combination therapy'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         We administer the agent with set targets in mind – (See
         <a class="local">
          'Set sedation-analgesia targets (scoring systems)'
         </a>
         below and
         <a class="local">
          'Administration'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3851735229">
         <span class="h3">
          Target etiology of the distress
         </span>
         <span class="headingEndMark">
          —
         </span>
         The appropriate initial pharmacologic agent for managing agitation should target the cause of the distress [
         <a href="#rid7">
          7
         </a>
         ]. In practice, more than one agent is typical, and the regimen may contain an agent for pain as well as an agent for anxiety/agitation and/or delirium. These agents are discussed below:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="local">
          'Pain or dyspnea'
         </a>
         below.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="local">
          'Anxiety/agitation'
         </a>
         below.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="local">
          'Delirium'
         </a>
         below.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="local">
          'Substance withdrawal'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4102578727">
         <span class="h4">
          Pain or dyspnea
         </span>
         <span class="headingEndMark">
          —
         </span>
         For distress due to dyspnea or pain, opioids are the agents of choice (eg,
         <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">
          fentanyl
         </a>
         or
         <a class="drug drug_general" data-topicid="8538" href="/z/d/drug information/8538.html" rel="external">
          hydromorphone
         </a>
         ). Fentanyl is generally the most commonly used opioid for intermittent or continuous use due to its rapid onset and short duration of action.
        </p>
        <p class="headingAnchor" id="H841439183">
         <span class="h5">
          Opioids
         </span>
         <span class="headingEndMark">
          —
         </span>
         Further details on opioid use for pain management are provided separately. (See
         <a class="medical medical_review" href="/z/d/html/2888.html" rel="external">
          "Pain control in the critically ill adult patient"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3221768616">
         <span class="h4">
          Anxiety/agitation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Our approach to managing anxiety/agitation is the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients with anxiety who do not need a continuous infusion (eg, some patients with mild to moderate alcohol withdrawal), intermittent dosing with benzodiazepines is appropriate. (See
         <a class="medical medical_review" href="/z/d/html/323.html" rel="external">
          "Management of moderate and severe alcohol withdrawal syndromes", section on 'Drug selection'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For severe agitation due to anxiety requiring a continuous infusion, we use
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         or
         <a class="drug drug_general" data-topicid="8897" href="/z/d/drug information/8897.html" rel="external">
          dexmedetomidine
         </a>
         rather than a benzodiazepine [
         <a href="#rid7">
          7
         </a>
         ]. We agree with the SCCM who favor
         <strong>
          non
         </strong>
         benzodiazepine agents. Exceptions include patients in whom benzodiazepines are first-line therapy for the underlying illness (eg, alcohol or substance withdrawal). (See
         <a class="local">
          'Substance withdrawal'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The avoidance of benzodiazepine infusions is supported by evidence that reports increased risk of delirium, mechanical ventilation days, and ICU length of stay when continuous infusions of benzodiazepines are used [
         <a href="#rid7">
          7
         </a>
         ]. Data also suggest that all three parameters are reduced by
         <a class="drug drug_general" data-topicid="8897" href="/z/d/drug information/8897.html" rel="external">
          dexmedetomidine
         </a>
         while mechanical ventilation days and ICU length of stay are reduced by
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         . These data are discussed below. (See
         <a class="local">
          'Propofol'
         </a>
         below and
         <a class="local">
          'Dexmedetomidine'
         </a>
         below and
         <a class="local">
          'Benzodiazepines'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3632573031">
         <span class="h5">
          Propofol
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          Propofol
         </a>
         appears to reduce ICU length of stay and mechanical ventilation days but not mortality compared with benzodiazepines [
         <a href="#rid28">
          28-30
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A 2018 network meta-analysis of 31 randomized trials (4491 patients) reported that benzodiazepines increase ICU length of stay compared with
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         (hazard ratio [HR] 3.62, 95% credible interval [CrI] 0.834-6.2) [
         <a href="#rid30">
          30
         </a>
         ]. Mortality rates were similar.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In one large, randomized, open label trial (included in the above meta-analysis),
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         infusions with daily infusion interruption (mean dose 24.4±16.3 mcg/kg/minute) resulted in a lower number of mechanical ventilation days compared with intermittent bolus
         <a class="drug drug_general" data-topicid="9573" href="/z/d/drug information/9573.html" rel="external">
          lorazepam
         </a>
         (median dose 11.5 mg/day) [
         <a href="#rid28">
          28
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3057567812">
         <span class="h5">
          Dexmedetomidine
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="8897" href="/z/d/drug information/8897.html" rel="external">
          Dexmedetomidine
         </a>
         may reduce mechanical ventilation days, ICU length of stay, and delirium compared with other agents (including benzodiazepines), but has no impact on mortality [
         <a href="#rid31">
          31-51
         </a>
         ]. As examples:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A 2022 meta-analysis of 77 randomized trials reported that compared with other sedatives,
         <a class="drug drug_general" data-topicid="8897" href="/z/d/drug information/8897.html" rel="external">
          dexmedetomidine
         </a>
         reduced the duration of mechanical ventilation (mean difference [MD] -1.8 hours, 95% CI -2.89 to -0.71), ICU length of stay (MD -0.32 days, 95% CI -0.42 to -0.22), and the risk of delirium (risk reduction 0.67, 95% CI 0.55-0.81) [
         <a href="#rid40">
          40
         </a>
         ]. However, dexmedetomidine also increased the risk of bradycardia by 6 percent and hypotension by 4 percent.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A 2018 network meta-analysis of 31 randomized trials (4491 patients) reported that compared with
         <a class="drug drug_general" data-topicid="8897" href="/z/d/drug information/8897.html" rel="external">
          dexmedetomidine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         and benzodiazepines were associated with an increased risk of delirium (HR 2.4, 95% CrI 0.304-21 and HR 2.59, 95% CrI 1.08-7.4, respectively) [
         <a href="#rid30">
          30
         </a>
         ]. Mortality rates were similar among all agents including propofol, benzodiazepines, and dexmedetomidine [
         <a href="#rid30">
          30
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         <a class="drug drug_general" data-topicid="8897" href="/z/d/drug information/8897.html" rel="external">
          Dexmedetomidine
         </a>
         may also decrease the need for alternative sedatives especially in patients withdrawing from alcohol where it may serve as a useful adjunct to benzodiazepines [
         <a href="#rid52">
          52-54
         </a>
         ], the details of which are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/323.html" rel="external">
          "Management of moderate and severe alcohol withdrawal syndromes", section on 'Alternative and contraindicated agents'
         </a>
         .)
        </p>
        <p>
         The comparative sedative activity of
         <a class="drug drug_general" data-topicid="8897" href="/z/d/drug information/8897.html" rel="external">
          dexmedetomidine
         </a>
         versus
         <a class="drug drug_general" data-topicid="9285" href="/z/d/drug information/9285.html" rel="external">
          clonidine
         </a>
         , another systemic central alpha-2-adrenoceptor agonist, in mechanically ventilated critically ill adults is being evaluated in an ongoing randomized clinical trial [
         <a href="#rid44">
          44
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H680789036">
         <span class="h5">
          Benzodiazepines
         </span>
         <span class="headingEndMark">
          —
         </span>
         Benzodiazepines are first-line agents for alcohol withdrawal. (See
         <a class="medical medical_review" href="/z/d/html/323.html" rel="external">
          "Management of moderate and severe alcohol withdrawal syndromes", section on 'Drug selection'
         </a>
         .)
        </p>
        <p>
         For other critically ill patients, benzodiazepines are effective anxiolytics but increase the risk of delirium (see
         <a class="medical medical_review" href="/z/d/html/1616.html" rel="external">
          "Sedative-analgesia in ventilated adults: Medication properties, dose regimens, and adverse effects", section on 'Adverse effects'
         </a>
         ), may prolong mechanical ventilation and ICU length of stay, and result in excess sedation for prolonged periods due to metabolite storage in adipose tissue. Benzodiazepine efficacy compared with
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         and
         <a class="drug drug_general" data-topicid="8897" href="/z/d/drug information/8897.html" rel="external">
          dexmedetomidine
         </a>
         are discussed above. (See
         <a class="local">
          'Propofol'
         </a>
         above and
         <a class="local">
          'Dexmedetomidine'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H1199744040">
         <span class="h4">
          Delirium
         </span>
         <span class="headingEndMark">
          —
         </span>
         Antipsychotics can be used intermittently as supplements to other sedatives for the treatment of hyperactive (agitated) delirium. While anti-psychotics are effective at treating delirium, they do not prevent or decrease the duration of delirium or mortality and are, therefore, not administered prophylactically. These data are discussed below. (See
         <a class="local">
          'Antipsychotics'
         </a>
         below.)
        </p>
        <p class="bulletIndent1">
         Choosing among the antipsychotics is individualized. For example, when rapid control of agitation is needed for acute hyperactive psychosis, we use intravenous (IV)
         <a class="drug drug_general" data-topicid="8516" href="/z/d/drug information/8516.html" rel="external">
          haloperidol
         </a>
         . In contrast, we use enteral agents (ie, atypical antipsychotics, such as
         <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">
          quetiapine
         </a>
         ) when chronic control is needed (eg, nocturnal psychosis or "sundowning," delirium limiting the ability of the patient to wean off sedative infusions in preparation for extubation). Further details regarding the efficacy of antipsychotics and treatment of delirium are provided separately. (See
         <a class="medical medical_review" href="/z/d/html/4823.html" rel="external">
          "Delirium and acute confusional states: Prevention, treatment, and prognosis", section on 'Antipsychotic medications'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4020476883">
         <span class="h5">
          Antipsychotics
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="8516" href="/z/d/drug information/8516.html" rel="external">
          Haloperidol
         </a>
         is the most common antipsychotic used to treat delirium in the ICU. Despite its widespread use in the past for delirium prevention, evidence among mechanically ventilated patients suggests that routine use of haloperidol does not prevent or decrease the duration of delirium and has no impact on mortality [
         <a href="#rid55">
          55-59
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         One randomized trial of 1789 critically ill patients at risk of delirium (defined as an anticipated ICU stay of at least two days) reported that 2 mg of
         <a class="drug drug_general" data-topicid="8516" href="/z/d/drug information/8516.html" rel="external">
          haloperidol
         </a>
         administered intravenously three times a day had no impact on the incidence of delirium, survival, duration of mechanical ventilation, length of stay, or any other measured outcome compared with placebo [
         <a href="#rid57">
          57
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In another randomized trial of 566 ICU patients with hyperactive or hypoactive delirium,
         <a class="drug drug_general" data-topicid="8516" href="/z/d/drug information/8516.html" rel="external">
          haloperidol
         </a>
         or the atypical antipsychotic
         <a class="drug drug_general" data-topicid="10040" href="/z/d/drug information/10040.html" rel="external">
          ziprasidone
         </a>
         had no impact on the number of days alive without delirium or coma, 30- or 90-day mortality, duration of mechanical ventilation, or time to ICU or hospital discharge compared with placebo [
         <a href="#rid58">
          58
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a randomized trial of 1000 mechanically ventilated patients, treatment of delirium with
         <a class="drug drug_general" data-topicid="8516" href="/z/d/drug information/8516.html" rel="external">
          haloperidol
         </a>
         did not alter the number of days alive outside the hospital at 90 days compared with placebo [
         <a href="#rid59">
          59
         </a>
         ]. The overall adverse event rate was low and was no different between the groups.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Atypical antipsychotics (
         <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">
          quetiapine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">
          olanzapine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9868" href="/z/d/drug information/9868.html" rel="external">
          risperidone
         </a>
         ,
         <a class="drug drug_general" data-topicid="10040" href="/z/d/drug information/10040.html" rel="external">
          ziprasidone
         </a>
         ) are oral agents that have also been used in adult ICU patients to treat delirium. While there is some evidence that oral atypical antipsychotics improve delirium in critically ill patients [
         <a href="#rid60">
          60,61
         </a>
         ], there is a paucity of studies that examine outcomes or compare the efficacy and safety of oral atypical antipsychotics with
         <a class="drug drug_general" data-topicid="8516" href="/z/d/drug information/8516.html" rel="external">
          haloperidol
         </a>
         or with one another. The few studies that exist suggest that the efficacy and safety of oral atypical antipsychotics may be similar to that of haloperidol [
         <a href="#rid60">
          60,62,63
         </a>
         ] and may reduce the use of other sedative agents [
         <a href="#rid64">
          64
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H368653316">
         <span class="h4">
          Substance withdrawal
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with agitation due to withdrawal syndromes should be treated consistent with the cause of withdrawal. As examples:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients experiencing alcohol or benzodiazepine withdrawal, treatment may consist of benzodiazepines,
         <a class="drug drug_general" data-topicid="9763" href="/z/d/drug information/9763.html" rel="external">
          phenobarbital
         </a>
         ,
         <a class="drug drug_general" data-topicid="8897" href="/z/d/drug information/8897.html" rel="external">
          dexmedetomidine
         </a>
         , or
         <a class="drug drug_general" data-topicid="9285" href="/z/d/drug information/9285.html" rel="external">
          clonidine
         </a>
         . Limited but contradictory evidence supports the use of phenobarbital for management of alcohol withdrawal syndrome in the ICU. A meta-analysis reported that phenobarbital may reduce length of hospital stay and intubation rates, but had no effect on ICU length of stay [
         <a href="#rid65">
          65
         </a>
         ]. Management of alcohol withdrawal is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/323.html" rel="external">
          "Management of moderate and severe alcohol withdrawal syndromes"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients experiencing opioid withdrawal, treatment should include reintroduction of an opioid, with level of use prior to admission and current organ function facilitating choice and dose of opioid. Other medications, such as
         <a class="drug drug_general" data-topicid="9285" href="/z/d/drug information/9285.html" rel="external">
          clonidine
         </a>
         and
         <a class="drug drug_general" data-topicid="9571" href="/z/d/drug information/9571.html" rel="external">
          loperamide
         </a>
         , may be used for additional symptomatic relief. Management of opiate withdrawal is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/306.html" rel="external">
          "Opioid withdrawal in the emergency setting"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1461072896">
         <span class="h3">
          Modifying variables
         </span>
         <span class="headingEndMark">
          —
         </span>
         Other factors that we consider when selecting a sedative-analgesic agent include the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pharmacokinetic modifying variables (eg, age, body weight, renal and hepatic function, drug interactions, history of alcohol or drug use). These variables affect onset, peak, and duration of sedation as well as potentiate adverse effects, particularly during deep or long-term sedation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Nonpharmacokinetic variables include the desired depth of sedation (eg, light or deep) and clinical status of the patient (eg, eg, presence of bradycardia, hypotension, obesity, long QTc).
        </p>
        <p>
        </p>
        <p>
         How these factors influence agent choice is variable. As examples:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients with bradycardia,
         <a class="drug drug_general" data-topicid="8897" href="/z/d/drug information/8897.html" rel="external">
          dexmedetomidine
         </a>
         is generally avoided since bradycardia is a common side effect of this agent. (See
         <a class="medical medical_review" href="/z/d/html/1616.html" rel="external">
          "Sedative-analgesia in ventilated adults: Medication properties, dose regimens, and adverse effects", section on 'Dexmedetomidine'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients with obesity, prolonged and high-dose benzodiazepines are often avoided since metabolites accumulate in adipose tissue, prolonging sedation and increasing length of stay and mechanical ventilation. (See
         <a class="medical medical_review" href="/z/d/html/1616.html" rel="external">
          "Sedative-analgesia in ventilated adults: Medication properties, dose regimens, and adverse effects", section on 'Benzodiazepines'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/584.html" rel="external">
          "Intensive care unit management of patients with obesity", section on 'Sedatives, analgesics, and neuromuscular blockers'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients with prolonged QTc interval or on agents that prolong the QTc interval  (
         <a class="graphic graphic_table graphicRef57431" href="/z/d/graphic/57431.html" rel="external">
          table 6
         </a>
         ), antipsychotics are avoided to decrease the risk of ventricular arrythmias. (See
         <a class="medical medical_review" href="/z/d/html/1616.html" rel="external">
          "Sedative-analgesia in ventilated adults: Medication properties, dose regimens, and adverse effects", section on 'Antipsychotics'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/116011.html" rel="external">
          "Acquired long QT syndrome: Clinical manifestations, diagnosis, and management"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients with significant hypotension,
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         and
         <a class="drug drug_general" data-topicid="8897" href="/z/d/drug information/8897.html" rel="external">
          dexmedetomidine
         </a>
         are often avoided or dosing limited since hypotension is a common adverse effect. A small degree of hypotension ("soft" blood pressure) is sometimes tolerated if the desired sedative effect is achieved and the patient is receiving vasopressors for another reason such as sepsis. (See
         <a class="medical medical_review" href="/z/d/html/1616.html" rel="external">
          "Sedative-analgesia in ventilated adults: Medication properties, dose regimens, and adverse effects", section on 'Propofol'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients with severe hypertriglyceridemia,
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         is contraindicated. (See
         <a class="medical medical_review" href="/z/d/html/1616.html" rel="external">
          "Sedative-analgesia in ventilated adults: Medication properties, dose regimens, and adverse effects", section on 'Propofol'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients in whom rapid sedation is required (eg, immediately following intubation, shivering during hypothermia) or rapid awakening is desirable (eg, patients who require frequent neurologic examinations),
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         is useful because it has a rapid onset and short duration of effect. (See
         <a class="medical medical_review" href="/z/d/html/1616.html" rel="external">
          "Sedative-analgesia in ventilated adults: Medication properties, dose regimens, and adverse effects", section on 'Properties'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The depth of sedation required for individual patients varies. While "light" sedation is the level recommended for most patients, deeper sedation may be required in patients with severe hypoxemic respiratory failure and ventilator dyssynchrony, patients undergoing procedures or transport, patients with cardiac devices, patients with elevated intracranial pressure, patients receiving medication for treatment of status epilepticus, or patients receiving NMBs.
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          Propofol
         </a>
         is the agent of choice for deep sedation because it allows relatively rapid emergence from deep levels of sedation. Recovery from deep sedation with benzodiazepines may be prolonged, and deep sedation may not be easily attained in many patients with
         <a class="drug drug_general" data-topicid="8897" href="/z/d/drug information/8897.html" rel="external">
          dexmedetomidine
         </a>
         alone. (See
         <a class="local">
          'Set sedation-analgesia targets (scoring systems)'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients with renal insufficiency, high dose
         <a class="drug drug_general" data-topicid="9573" href="/z/d/drug information/9573.html" rel="external">
          lorazepam
         </a>
         should be avoided since the diluent, polypropylene glycol, can accumulate and cause lactic acidosis. This adverse effect is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1616.html" rel="external">
          "Sedative-analgesia in ventilated adults: Medication properties, dose regimens, and adverse effects", section on 'Propylene glycol toxicity'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         The pharmacologic properties of individual agents are provided separately  (
         <a class="graphic graphic_table graphicRef79667" href="/z/d/graphic/79667.html" rel="external">
          table 5
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/1616.html" rel="external">
          "Sedative-analgesia in ventilated adults: Medication properties, dose regimens, and adverse effects"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1357229497">
         <span class="h2">
          Combination therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pharmacologic needs range widely. While some patients require minimal or no sedation (eg, severe traumatic brain injury), others require deep sedation to be mechanically ventilated without discomfort, agitation, or asynchrony (eg, severe acute respiratory distress). If the clinician has trouble achieving the set target, dosing is maximized as tolerated and additional agents are administered. Importantly, we avoid polypharmacy such that daily evaluation of both routine and as-needed sedatives is important. (See
         <a class="local">
          'Continuous reassessment'
         </a>
         below.)
        </p>
        <p>
         In practice, most patients often need more than one class of drug (typically two) since the etiology of distress is multifactorial. As an example, for a patient whose agitation is due to anxiety and pain,
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         plus an intermittent opioid is appropriate. For patients who are intubated and mechanically ventilated and not able to clearly communicate the source of agitation, we also often administer propofol with an intermittent analgesic agent (eg,
         <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">
          fentanyl
         </a>
         ) [
         <a href="#rid7">
          7
         </a>
         ]. Patients with alcohol withdrawal may require benzodiazepines (or
         <a class="drug drug_general" data-topicid="9763" href="/z/d/drug information/9763.html" rel="external">
          phenobarbital
         </a>
         ) and supplemental atypical antipsychotic for heightened periods of delusional agitation;
         <a class="drug drug_general" data-topicid="8897" href="/z/d/drug information/8897.html" rel="external">
          dexmedetomidine
         </a>
         infusion may also be a useful adjunct in this population for difficult to control symptoms.
        </p>
        <p>
         The value of combination therapy was supported by a trial that randomly assigned 30 mechanically ventilated patients to receive
         <a class="drug drug_general" data-topicid="9650" href="/z/d/drug information/9650.html" rel="external">
          midazolam
         </a>
         alone or midazolam plus
         <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">
          fentanyl
         </a>
         [
         <a href="#rid66">
          66
         </a>
         ]. Midazolam plus fentanyl maintained sedation level goals better, decreased the dose of the primary agent, added analgesia, and did not appreciably increase the likelihood of prolonged sedation. There were no differences in hemodynamic or respiratory adverse effects. Two patients treated with the combination regimen developed ileus, compared with none in the midazolam group.
        </p>
        <p class="headingAnchor" id="H3353359508">
         <span class="h2">
          Set sedation-analgesia targets (scoring systems)
         </span>
         <span class="headingEndMark">
          —
         </span>
         We use scoring systems for the presumed cause of distress to target a set sedation level. As an example, if the distress is due to pain and an opioid is initiated, then assessment using a pain scale is appropriate. If the goal of therapy is anxiolysis/sedation, then a scale assessing level of sedation should be used. On many occasions, more than one scoring system is used since agitation/distress is often multifactorial.
        </p>
        <p>
         Once the appropriate scoring system(s) is selected, we titrate or taper the sedative-analgesic medication to meet the therapeutic goals. One caveat of scoring systems is that reference standards do not exist, underscoring the importance of simultaneous clinical evaluation [
         <a href="#rid67">
          67
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Anxiety/sedation scale
         </strong>
         – There are numerous scoring systems to assess anxiety/agitation that are valid and reliable in adults who are critically ill and mechanically ventilated [
         <a href="#rid68">
          68-72
         </a>
         ]. The most common scale used is the Richmond Agitation-Sedation Scale (RASS)  (
         <a class="graphic graphic_table graphicRef57874" href="/z/d/graphic/57874.html" rel="external">
          table 7
         </a>
         ), although the Riker Sedation-Agitation Scale is an alternative [
         <a href="#rid7">
          7,10
         </a>
         ]. Other scoring systems include the Motor Activity Assessment Scale, Minnesota Sedation Assessment Tool, Ramsay Sedation Scale  (
         <a class="graphic graphic_table graphicRef65842" href="/z/d/graphic/65842.html" rel="external">
          table 8
         </a>
         ), Bizek Agitation Scale, Sheffield Scale, and COMFORT Scale [
         <a href="#rid73">
          73-76
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For most patients, we target a "light" level of sedation. However, there is no consensus regarding the definition of "light" sedation. While in intubated patients the ideal sedation goal is for the patient to be awake and comfortable with minimal to no distress (eg, 0 on the RASS scale)  (
         <a class="graphic graphic_table graphicRef57874" href="/z/d/graphic/57874.html" rel="external">
          table 7
         </a>
         ), a target range from 0 (alert and calm) to -1 (drowsy) is more realistic. Data that support "light" sedation targets are derived from an SCCM meta-analysis of eight studies where light sedation was associated with a shorter time to extubation (mean difference -0.77 days, 95% CI -2.04 to -0.50) and a reduced tracheostomy rate (risk ratio [RR] 0.57, 95% CI 0.41-0.8) [
         <a href="#rid7">
          7
         </a>
         ]. Light sedation was not associated with a reduction in 90-day mortality, delirium (RR 0.96, 95% CI 0.80-1.16), posttraumatic stress disorder, depression, or self-extubation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         However, some critically ill mechanically ventilated patients require a very deep level of sedation-analgesia to control agitation or pain. As examples, deeper sedation may be desired in patients with severe hypoxemic respiratory failure and ventilator dyssynchrony, patients undergoing procedures or transport, patients with cardiac devices, patients with elevated intracranial pressure, patients receiving medication for treatment of status epilepticus, or patients receiving NMBs.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The goal for depth of sedation should be frequently reassessed and adjusted as the patient's sedation requirement becomes more apparent and the critical illness evolves. (See
         <a class="local">
          'Continuous reassessment'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pain scales
         </strong>
         – The primary goal of analgesia is to provide optimal patient comfort, which is highly subjective. We assess the response to analgesia using similar assessment tools to those used for the initial evaluation. These details are described separately. (See
         <a class="medical medical_review" href="/z/d/html/2888.html" rel="external">
          "Pain control in the critically ill adult patient"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Delirium scales
         </strong>
         – The primary goal of treating delirium is that the patient be calm and cooperative or back to their baseline mental status. We assess the response to treatment using similar assessment tools to those used for the initial assessment. These tools are described separately. (See
         <a class="local">
          'Assessment anxiety, pain, delirium'
         </a>
         above and
         <a class="local">
          'Delirium'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Targets during paralysis
         </strong>
         – For patients receiving NMBs (which are
         <strong>
          not
         </strong>
         sedatives), deep levels of sedation and assurance of analgesia should be established prior to the administration of paralytics if feasible. Although neuromuscular monitoring (eg, train-of-four) is used routinely during paralysis, clinical targets should additionally guide NMB dosing (eg, ventilator synchrony, avoidance of shivering during hypothermia). Setting targets and monitoring patients on NMBs is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/114324.html" rel="external">
          "Monitoring neuromuscular blockade"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2763635511">
         <span class="h2">
          Administration
         </span>
         <span class="headingEndMark">
          —
         </span>
         Once an agent(s) is chosen, the initial dose and route of administration is selected.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Initial dosing
         </strong>
         – Suggested initial and continuous infusion dosing for common agents are shown in the table  (
         <a class="graphic graphic_table graphicRef79667" href="/z/d/graphic/79667.html" rel="external">
          table 5
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The initial dose of a sedative-analgesic agent depends upon the desired level of sedation, ability to tolerate the drug (including hemodynamic and respiratory status), and factors that may affect drug metabolism (ie, patient age, body weight, renal function, hepatic function, drug interactions (see
         <a class="local">
          'Modifying variables'
         </a>
         above)). Higher doses are appropriate for deeper sedation, larger patients, and patients with a history of alcohol or drug use while lower doses are appropriate for lighter sedation, smaller patients, patients with advanced age, and diminished renal or hepatic function.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Route of administration
         </strong>
         – We typically initiate sedatives intravenously. Whether a continuous infusion or intermittent IV dosing is administered is an individualized decision. Although more labor intensive, intermittent IV bolus dosing is less likely to result in drug accumulation compared with continuous infusions. Some experts switch to a continuous infusion when patients require intermittent dosing more often than every two hours. Infusion strategies that prioritize protocolized titrations to light level of sedation or daily interruption are appropriate. Protocolization, daily interruption, and sedation targets are discussed separately. (See
         <a class="local">
          'Set sedation-analgesia targets (scoring systems)'
         </a>
         above and
         <a class="local">
          'Avoiding oversedation'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The number of agents required to achieve adequate sedation vary. For some patients, intermittent IV bolus sedation is sufficient to maintain light sedation and patient cooperation with care (eg, mild to moderate alcohol withdrawal, patients with severe hypoxic encephalopathy following resuscitation from cardiac arrest, hypoactive delirium). In contrast, other patients require a continuous infusion to manage severe agitation (eg, patients with hyperactive delirium, severe agitation from opiate withdrawal, coronavirus disease 2019 [COVID-19]-related delirium). Some patients with severe agitation may also need several agents with more than one continuous infusion with or without supplemental bolus infusions (eg, COVID-19 patients). (See
         <a class="local">
          'Combination therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1283304848">
         <span class="h1">
          MAINTENANCE AND MONITORING
         </span>
        </p>
        <p class="headingAnchor" id="H764507577">
         <span class="h2">
          Role of the pharmacist
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although not universally available, we advocate for the involvement of a critical care pharmacist, particularly during daily rounds [
         <a href="#rid77">
          77,78
         </a>
         ]. Since agent selection can be complex given the multitude of modifying variables in critically ill patients, the clinical pharmacist can optimize therapy, help to reduce drug interactions, improve patient monitoring, and avoid adverse effects. Pharmacists are also key in recognizing discontinued home medications that may exacerbate anxiety, delirium, and pain or agitation in critically ill patients.
        </p>
        <p>
         Data support the role of the pharmacist. One meta-analysis of 14 studies reported that intervention of critical care pharmacists as part of the multidisciplinary intensive care unit (ICU) team reduced the likelihood of mortality compared with no intervention (odds ratio 0.78, 95% CI 0.73-0.83) [
         <a href="#rid77">
          77
         </a>
         ]. Pharmacist involvement also reduced length of stay and drug-related adverse events.
        </p>
        <p class="headingAnchor" id="H3992585746">
         <span class="h2">
          Continuous reassessment
         </span>
         <span class="headingEndMark">
          —
         </span>
         Once the target goal of sedation is reached, attention should be directed towards monitoring and avoiding excess sedation. This involves frequent reassessment of sedative-analgesic requirements to achieve simultaneous patient comfort in an awake and alert patient. The assessment systems described above allow the clinician to taper sedation when the sedation level is too deep and to titrate sedation when it is too light (see
         <a class="local">
          'Assessment anxiety, pain, delirium'
         </a>
         above and
         <a class="local">
          'Set sedation-analgesia targets (scoring systems)'
         </a>
         above). This requires hourly bedside assessment by nursing staff as well as daily assessment during rounds that are focused on avoiding oversedation and weaning sedation to the lowest achievable effective dose. As the critical illness is treated, the sedative requirement should fall.
        </p>
        <p class="headingAnchor" id="H1800642447">
         <span class="h2">
          Avoiding oversedation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Excess sedation prolongs the duration of mechanical ventilation [
         <a href="#rid79">
          79-81
         </a>
         ]. Three strategies have been shown to reduce the impact of oversedation on prolonged mechanical ventilation. Although the optimal method is unknown, many ICUs practice one of these approaches and the Society of Critical Care Medicine state that "light" sedation can be achieved in most patients most of the time using any one of these methods [
         <a href="#rid7">
          7
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Intermittent intravenous (IV) boluses of medication (including analgesia without sedatives, sometimes referred to as "no sedation"). (See
         <a class="local">
          'Intermittent bolus'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Daily sedation interruption (DSI) of continuous infusions. (See
         <a class="local">
          'Daily interruption of sedation'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Detailed protocols that incorporate one or both of the above approaches. (See
         <a class="local">
          'Nursing protocolized sedation'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p>
         Benefits may be limited if two methods are being concurrently used. This was illustrated by a multicenter trial in which 430 mechanically ventilated patients were randomly assigned to receive protocolized sedation (PS) alone or PS plus daily interruption of their continuous sedative-analgesic infusion (PS+DI) [
         <a href="#rid82">
          82
         </a>
         ]. Time to extubation, rates of unintentional removal of medical devices, ICU delirium, diagnostic neuroimaging, and tracheostomy rates were similar. This study suggests PS alone can effectively achieve the minimal effective sedative dose requirement for patients; there is likely no benefit associated with interrupting the minimal effective dose.
        </p>
        <p class="headingAnchor" id="H173847244">
         <span class="h3">
          Intermittent bolus
         </span>
         <span class="headingEndMark">
          —
         </span>
         Intermittent bolus sedation involves only administering boluses of IV sedation, typically opiates or benzodiazepines, on a regular basis or when needed. For example, patients with alcohol withdrawal can often be managed successfully with an around-the-clock intermittent benzodiazepine supplemented with as-needed doses of the same benzodiazepine.
        </p>
        <p>
         Limited older data support intermittent boluses of sedatives to decrease the risk of prolonged mechanical ventilation due to oversedation. One observational study of 242 patients compared the duration of mechanical ventilation among patients who received a continuous sedative-analgesic infusion (not targeted to any specific level of sedation) with those who received either intermittent or no sedative-analgesic infusions, based on a nursing protocol [
         <a href="#rid79">
          79
         </a>
         ]. The group that received intermittent or no medication had a shorter duration of mechanical ventilation than the group that received a continuous infusion (median 56 versus 185 hours). However, sedation level in the continuous infusion group was not targeted to a "light" level with DSI. This may explain why no difference was found in a separate study when intermittent sedation was compared with "light" sedation [
         <a href="#rid83">
          83
         </a>
         ]. These data are discussed below. (See
         <a class="local">
          'Daily interruption of sedation'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H1687089813">
         <span class="h3">
          Daily interruption of sedation
         </span>
         <span class="headingEndMark">
          —
         </span>
         DSI refers to discontinuation of the continuous sedative-analgesic infusion until the patient is awake and following instructions or uncomfortable/agitated and deemed to require the resumption of sedation. The rationale for DSI is that it facilitates assessment of the patient's underlying neurologic status as well as the patient's need for ongoing sedation.
        </p>
        <p>
         Randomized trials and meta-analyses report possible benefit from DSI with regard to reducing duration of mechanical ventilation and length of stay [
         <a href="#rid28">
          28,79-82,84-93
         </a>
         ]. However, there is considerable heterogeneity among trials that limits their interpretation. As examples:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A 2014 meta-analysis of nine trials reported that compared with strategies that do not utilize DSI, DSI resulted in marginal reductions in the duration of mechanical ventilation (13 percent), ICU and hospital length of stay (10 and 6 percent, respectively) [
         <a href="#rid92">
          92
         </a>
         ]. The risk of death, rate of accidental endotracheal tube removal, incidence of new onset delirium, and doses of sedative administered were similar. The confidence intervals were wide, which indicates imprecision and limits interpretation of the analysis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A subsequent trial compared daily interruption of "light sedation" (defined as -2 to -3 on the Richmond Agitation and Sedation Scale  (
         <a class="graphic graphic_table graphicRef57874" href="/z/d/graphic/57874.html" rel="external">
          table 7
         </a>
         ) with "no sedation" (intermittent analgesia with IV
         <a class="drug drug_general" data-topicid="9788" href="/z/d/drug information/9788.html" rel="external">
          morphine
         </a>
         ) in 710 mechanically ventilated patients [
         <a href="#rid83">
          83
         </a>
         ]. There were similar rates of 90-day mortality (37 versus 42 percent), the number of ICU- and ventilator-free days, and days free from coma or delirium. Although the thromboembolic event rate was higher in the sedation group, the total event rate was low (1.5 percent). The inclusion criteria were very specific (among 2300 screened, only 710 underwent randomization) suggesting that the approach of "no sedation" is not generalizable to all mechanically ventilated patients. In addition, the trial may have been underpowered to detect a difference in mortality.
        </p>
        <p>
        </p>
        <p>
         While initially there were concerns related to patient safety during DSI [
         <a href="#rid94">
          94,95
         </a>
         ], such as posttraumatic stress disorder, self-extubation or line removal, and myocardial ischemia, newer data do not support these concerns [
         <a href="#rid90">
          90,91,96,97
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2279438668">
         <span class="h3">
          Nursing protocolized sedation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Nursing protocolized-sedation is defined as a bedside sedation protocol implemented by nurses that directs sedative choices and medication titration to achieve targeted sedation scores. They usually incorporate components of intermittent bolus infusions and/or DSI.
        </p>
        <p class="bulletIndent1">
         Data support protocol use [
         <a href="#rid93">
          93,98-101
         </a>
         ]. A meta-analysis of six randomized trials of mechanically ventilated patients in closed nonspecialty ICUs reported that compared with usual care, protocolized sedation was associated with a rate reduction in overall mortality (15 percent), length of hospital stay (3.5 days), and tracheostomy (31 percent) [
         <a href="#rid93">
          93
         </a>
         ]. The duration of mechanical ventilation and rate of self-extubation or reintubation were similar.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1702129815">
         <span class="h1">
          REFRACTORY AGITATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with refractory agitation, three or four agents from different classes may be required. In this population, second-line agents, such as barbiturates and
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          ketamine
         </a>
         , may also need to be considered. Use of paralysis is rare (eg, persistent ventilator dyssychrony, hypothermia-induced shivering despite deep sedation).
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          Ketamine
         </a>
         is a US Food and Drug Administration-approved anesthetic agent. Off-label uses include procedural sedation/analgesia, treatment of extreme agitation, and treatment of pain as an adjunct to opioids [
         <a href="#rid7">
          7
         </a>
         ]. Use of ketamine as an adjunctive analgo-sedative in critically ill mechanically ventilated patients was common during the COVID-19 pandemic [
         <a href="#rid102">
          102,103
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Since
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          ketamine
         </a>
         has analgesic properties, it has been shown to reduce opioid requirements [
         <a href="#rid104">
          104,105
         </a>
         ]. Small randomized studies of patients with burns also suggested that during painful procedures, oral ketamine provided better analgesia than
         <a class="drug drug_general" data-topicid="8897" href="/z/d/drug information/8897.html" rel="external">
          dexmedetomidine
         </a>
         or the combination of
         <a class="drug drug_general" data-topicid="9650" href="/z/d/drug information/9650.html" rel="external">
          midazolam
         </a>
         ,
         <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">
          acetaminophen
         </a>
         , and
         <a class="drug drug_general" data-topicid="9291" href="/z/d/drug information/9291.html" rel="external">
          codeine
         </a>
         (eg, dressing changes) [
         <a href="#rid106">
          106,107
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2888.html" rel="external">
          "Pain control in the critically ill adult patient", section on 'Ketamine'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/14989.html" rel="external">
          "Management of burn wound pain and itching", section on 'Nonopioid analgesics'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The role of
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          ketamine
         </a>
         as an induction agent for intubation is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/271.html" rel="external">
          "Induction agents for rapid sequence intubation in adults for emergency medicine and critical care", section on 'Ketamine'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Use of
         <a class="drug drug_general" data-topicid="9763" href="/z/d/drug information/9763.html" rel="external">
          phenobarbital
         </a>
         is rarely needed to manage agitation, although limited but contradictory evidence supports its use for management of alcohol withdrawal syndrome in the intensive care unit (ICU). A meta-analysis reported that phenobarbital may reduce length of hospital stay and intubation rates compared with benzodiazepines, but had no effect on ICU length of stay [
         <a href="#rid65">
          65
         </a>
         ]. Management of alcohol withdrawal is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/323.html" rel="external">
          "Management of moderate and severe alcohol withdrawal syndromes"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients who exhibit dyssynchrony despite appropriate adjustments to ventilator settings and deep sedation, the addition of a neuromuscular blocker is sometimes needed, ensuring that patients remain deeply sedated with analgo-sedatives. Sedation targets during paralysis and indications for paralysis are discussed separately. (See
         <a class="local">
          'Set sedation-analgesia targets (scoring systems)'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/1590.html" rel="external">
          "Neuromuscular blocking agents in critically ill patients: Use, agent selection, administration, and adverse effects"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H19">
         <span class="h1">
          DISCONTINUATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         When pharmacologic sedation is no longer necessary, we wean sedatives with a goal of discontinuation. General principles include the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Order of medication weaning – For patients receiving more than one sedative-analgesic medication (eg,
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         and an opioid) and in whom pain can be assessed, the opioid should be tapered last so that the patient does not awake in pain. For patients in whom pain is able to be assessed, agents may be weaned simultaneously and pain treated.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Rate of weaning – The rate of medication reduction should be individualized and depends upon the duration of sedation and manifestations of potential addiction (ie, tachyphylaxis [increased dosage required over time to achieve the same level of sedation]). Generally speaking, the following applies:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         If the sedative-analgesic agent has been administered for a short duration (≤7 days), discontinuation over a short period of time is acceptable (eg, over hours).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         If the sedative-analgesic agent has been administered for &gt;7 days and the patient exhibits evidence of tachyphylaxis, a gradual reduction may be necessary (eg, approximately 10 to 25 percent per day).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In some patients who have received significant amounts of sedation for &gt;7 days who are deeply sedated from prolonged accumulation of medication, abrupt discontinuation may be appropriate. The rationale for this approach is that there may be a delay (ie, days) between the moment that reduction of the sedative-analgesic agent begins, and the patient begins to awaken, particularly following long-term therapy. This is because lipophilic drugs accumulate in tissue stores and must be mobilized for elimination (eg, benzodiazepines and opiates).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Observation for withdrawal symptoms – During sedative-analgesic medication weaning, the patient should be closely observed for withdrawal symptoms, which are common in this setting (up to one-third of patients) [
         <a href="#rid108">
          108
         </a>
         ]. In general, higher doses of benzodiazepines and opiates confer a higher risk of withdrawal.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Our approach is the following:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Benzodiazepine withdrawal – For those with troublesome benzodiazepine withdrawal, transitioning to intermittent intravenous or oral
         <a class="drug drug_general" data-topicid="9573" href="/z/d/drug information/9573.html" rel="external">
          lorazepam
         </a>
         (eg, 0.5 to 1 mg every 6 to 12 hours) may help protect the patient from developing withdrawal symptoms as the continuous benzodiazepine infusion is being reduced.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Opiate withdrawal – Several strategies have been proposed for preventing opioid withdrawal, including de-escalating the dose, converting to a longer-acting oral equivalent, converting to a long-acting barbiturate (eg,
         <a class="drug drug_general" data-topicid="9763" href="/z/d/drug information/9763.html" rel="external">
          phenobarbital
         </a>
         ), and adding an alpha-2-agonist (
         <a class="drug drug_general" data-topicid="9285" href="/z/d/drug information/9285.html" rel="external">
          clonidine
         </a>
         ,
         <a class="drug drug_general" data-topicid="8897" href="/z/d/drug information/8897.html" rel="external">
          dexmedetomidine
         </a>
         ) [
         <a href="#rid109">
          109,110
         </a>
         ]. However, there are no controlled trials of any strategy and there is no consensus as to the best strategy. Data are limited to case reports, including two reports in which dexmedetomidine was initiated at a dose of 0.7 mcg/kg/hour (with or without a loading dose) and successfully facilitated opioid withdrawal [
         <a href="#rid111">
          111,112
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/120967.html" rel="external">
          "Opioid tapering for patients with chronic pain", section on 'Opioid tapering strategy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="8897" href="/z/d/drug information/8897.html" rel="external">
          Dexmedetomidine
         </a>
         withdrawal – For those with troublesome dexmedetomidine withdrawal (eg, agitation, delirium, tachycardia, elevated systolic blood pressure) transitioning to oral
         <a class="drug drug_general" data-topicid="9285" href="/z/d/drug information/9285.html" rel="external">
          clonidine
         </a>
         , a centrally acting alpha-2-agonist may be a safe way to minimize symptoms and signs of withdrawal. Clonidine is initiated at a dose of 0.2 to 0.3 mg every six hours and then tapered by increasing the dosage interval every 24 hours over the next several days (eg, five to six days) [
         <a href="#rid113">
          113-115
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The value of institutional policies is unclear. One observational study reported that most institutions do not have a policy/protocol for sedative weaning and when available, they are used in only a small percentage of patients [
         <a href="#rid116">
          116
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2659871124">
         <span class="h1">
          INVESTIGATIONAL AGENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9887" href="/z/d/drug information/9887.html" rel="external">
          Sevoflurane
         </a>
         and
         <a class="drug drug_general" data-topicid="9062" href="/z/d/drug information/9062.html" rel="external">
          baclofen
         </a>
         are investigational agents that have been studied as analgo-sedatives in critically ill patients.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Data describing
         <a class="drug drug_general" data-topicid="9887" href="/z/d/drug information/9887.html" rel="external">
          sevoflurane
         </a>
         use in critically ill patients are limited. A trial randomly assigned 60 mechanically ventilated intensive care unit (ICU) patients to sedation with sevoflurane,
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         , or
         <a class="drug drug_general" data-topicid="9650" href="/z/d/drug information/9650.html" rel="external">
          midazolam
         </a>
         [
         <a href="#rid117">
          117
         </a>
         ]. All of the patients received
         <a class="drug drug_general" data-topicid="9854" href="/z/d/drug information/9854.html" rel="external">
          remifentanil
         </a>
         for analgesia, most were relatively young trauma patients, and 47 completed the trial. The median duration of sedation in the sevoflurane group was 50 hours (range 39 to 71 hours). Wake-up time and time to extubation were significantly shorter in the sevoflurane group compared with the propofol or midazolam groups. The study had too few events to conclusively detect differences in ICU length of stay or mortality.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Early data suggested that
         <a class="drug drug_general" data-topicid="9062" href="/z/d/drug information/9062.html" rel="external">
          baclofen
         </a>
         may mitigate alcohol craving in patients with alcohol use disorder [
         <a href="#rid118">
          118,119
         </a>
         ]. A subsequent randomized trial used high-dose oral baclofen (50 to 150 mg per day) for the management of agitation in 314 mechanically ventilated patients who had unhealthy alcohol use [
         <a href="#rid120">
          120
         </a>
         ]. Baclofen reduced the proportion of patients who experienced at least one agitation-related event compared with placebo (19.7 versus 29.7 percent; eg, self-extubation, removal of venous catheters). Baclofen had no impact on 28-day ICU mortality and was associated with a longer duration of mechanical ventilation and ICU length of stay. The most common adverse effect was delayed awakening; others included stroke, seizure, and bradycardia. Several flaws in study design, including the lack of standardized baclofen dosing and inaccurate assessment of alcohol consumption, limit interpretation and generalization of this study.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4056489512">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/120246.html" rel="external">
          "Society guideline links: Nonprocedural sedation"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H20">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Initial management
         </strong>
         – Before a sedative-analgesic agent is initiated, the underlying critical illness should be treated and the etiology of the distress identified and addressed (eg, anxiety, pain, and/or delirium). Nonpharmacologic strategies should be implemented simultaneously (eg, reassurance and frequent communication with the patient, music therapy). (See
         <a class="local">
          'Initial assessment and treatment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pharmacologic sedation
         </strong>
         – For patients in whom treatment of the underlying illness and nonpharmacologic interventions do not sufficiently control the agitation, pharmacologic sedation is appropriate. (See
         <a class="local">
          'Initiating sedative-analgesics'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Agent selection
         </strong>
         – Selection of an agent must be individualized according to the etiology of distress and any existing modifying variables, such as interactions with other drugs and clinical status of the patient. In most cases, more than one agent is needed (eg, anxiolytic/sedative plus analgesic agents)  (
         <a class="graphic graphic_table graphicRef79667" href="/z/d/graphic/79667.html" rel="external">
          table 5
         </a>
         ). (See
         <a class="local">
          'Selection of agent(s)'
         </a>
         above and
         <a class="local">
          'Combination therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         For most patients with agitation due to anxiety that requires a continuous intravenous (IV) sedative infusion, we suggest
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         or
         <a class="drug drug_general" data-topicid="8897" href="/z/d/drug information/8897.html" rel="external">
          dexmedetomidine
         </a>
         rather than a benzodiazepine (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ). This choice is based upon evidence that suggests increased risk of delirium, mechanical ventilation days, and intensive care unit (ICU) length of stay when continuous infusions of benzodiazepines are used. Data also suggest that all three parameters are reduced by dexmedetomidine while mechanical ventilation days and ICU length of stay are reduced by propofol. (See
         <a class="local">
          'Anxiety/agitation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         The exception is patients with alcohol withdrawal in whom benzodiazepines are first-line therapy; these details are provided separately (See
         <a class="medical medical_review" href="/z/d/html/323.html" rel="external">
          "Management of moderate and severe alcohol withdrawal syndromes"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Most patients who are mechanically ventilated have pain and many have dyspnea. For patients with distress due to dyspnea or pain, short-acting titrating bolus or continuous opioids are required. Requirements are variable, ranging from an intermittent bolus or continuous infusion.
         <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">
          Fentanyl
         </a>
         is the most common agent used, although
         <a class="drug drug_general" data-topicid="8538" href="/z/d/drug information/8538.html" rel="external">
          hydromorphone
         </a>
         ,
         <a class="drug drug_general" data-topicid="9854" href="/z/d/drug information/9854.html" rel="external">
          remifentanil
         </a>
         , and
         <a class="drug drug_general" data-topicid="9788" href="/z/d/drug information/9788.html" rel="external">
          morphine
         </a>
         are alternatives. Further details on opioids for pain management are provided separately. (See
         <a class="medical medical_review" href="/z/d/html/2888.html" rel="external">
          "Pain control in the critically ill adult patient"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Agitated delirium is typically treated with antipsychotics. For patients with distress due to acute psychosis, we suggest a trial of
         <a class="drug drug_general" data-topicid="8516" href="/z/d/drug information/8516.html" rel="external">
          haloperidol
         </a>
         rather than other agents (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ).The IV formulation, administered intermittently, is often required since continuous infusions are not available. For patients with less acute psychosis (eg, nocturnal psychosis or "sundowning"), we suggest using longer-acting enteral agents (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Options include atypical antipsychotics, such as
         <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">
          quetiapine
         </a>
         , respiridone, and olanazepine. Further details regarding the efficacy of antipsychotics and treatment of delirium are provided separately. (See
         <a class="medical medical_review" href="/z/d/html/4823.html" rel="external">
          "Delirium and acute confusional states: Prevention, treatment, and prognosis", section on 'Antipsychotic medications'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Patients with agitation due to withdrawal syndromes should be treated consistent with the cause of withdrawal, the details of which are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/323.html" rel="external">
          "Management of moderate and severe alcohol withdrawal syndromes"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/306.html" rel="external">
          "Opioid withdrawal in the emergency setting"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Sedation goals
         </strong>
         – Clinical evaluation and scoring systems are used to set sedation targets and to follow the response to therapy. (See
         <a class="local">
          'Set sedation-analgesia targets (scoring systems)'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Anxiety/sedation – In most mechanically ventilated patients, we suggest targeting a "light" level of sedation (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ). The most common scale used is the Richmond Agitation-Sedation Scale (RASS)  (
         <a class="graphic graphic_table graphicRef57874" href="/z/d/graphic/57874.html" rel="external">
          table 7
         </a>
         ); we typically target a RASS score of 0 to -1). In this population, a light sedation level has been shown to decrease mechanical ventilation days and tracheostomy rates. However, some patients require a very deep level of sedation-analgesia (eg, patients with refractory hypoxemia and ventilator dyssynchrony, with intracranial hypertension, undergoing diagnostic procedures). (See
         <a class="local">
          'Set sedation-analgesia targets (scoring systems)'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Pain – In patients who can communicate, we use unidimensional scales (eg, a 0 to 10-point scale on which 10 represents the worst pain  (
         <a class="graphic graphic_figure graphicRef72905" href="/z/d/graphic/72905.html" rel="external">
          figure 1
         </a>
         )). In nonverbal patients, we use multidimensional scales, such as the Behavioral Pain Scale (BPS)  (
         <a class="graphic graphic_table graphicRef103690" href="/z/d/graphic/103690.html" rel="external">
          table 1
         </a>
         ) and the Critical Care Pain Observation Tool (CPOT)  (
         <a class="graphic graphic_table graphicRef103691" href="/z/d/graphic/103691.html" rel="external">
          table 2
         </a>
         ). The goal of pain control is to ensure comfort. Further details regarding pain control are provided separately. (See
         <a class="local">
          'Set sedation-analgesia targets (scoring systems)'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/2888.html" rel="external">
          "Pain control in the critically ill adult patient", section on 'Goals of pain control'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Delirium – We use the confusion assessment method for the intensive care unit (CAM-ICU) scale or the Intensive Care Delirium Screening Checklist (ICDSC) to detect delirium. The goal is to have the patient be calm and cooperative and return back to their baseline mental status. (See
         <a class="local">
          'Set sedation-analgesia targets (scoring systems)'
         </a>
         above and
         <a class="local">
          'Assessment anxiety, pain, delirium'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Maintenance and monitoring
         </strong>
         – Our approach is the following:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         All patients should be frequently reassessed to determine whether their sedative-analgesic medication needs to be titrated or tapered. This requires hourly bedside assessment by nursing staff as well as daily assessment during rounds. (See
         <a class="local">
          'Continuous reassessment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Although the optimal method is unknown, choosing one of the following approaches should help avoid oversedation (see
         <a class="local">
          'Avoiding oversedation'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Intermittent boluses rather than continuous dosing of medication (including analgesia without sedatives, sometimes referred to as "no sedation"). (See
         <a class="local">
          'Intermittent bolus'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Daily sedation interruption (DSI) of continuous infusions. (See
         <a class="local">
          'Daily interruption of sedation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Protocolized sedation that incorporates components of intermittent bolus sedation or DSI. (See
         <a class="local">
          'Nursing protocolized sedation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Weaning
         </strong>
         – When pharmacologic sedation is no longer necessary, we wean sedatives with a goal of discontinuation. The rate of reduction must be individualized and depends upon the duration of sedation and manifestations of potential addiction (eg, tachyphylaxis). Tapering agents in parallel is often performed except when opioids are coadministered and are generally tapered last so that the patient does not awake in pain. If there is difficulty weaning due to withdrawal symptoms, transitioning to an oral or intermittent agent of the same class may be useful. (See
         <a class="local">
          'Discontinuation'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Hansen-Flaschen J. Improving patient tolerance of mechanical ventilation. Challenges ahead. Crit Care Clin 1994; 10:659.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lewis KS, Whipple JK, Michael KA, Quebbeman EJ. Effect of analgesic treatment on the physiological consequences of acute pain. Am J Hosp Pharm 1994; 51:1539.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           May AD, Parker AM, Caldwell ES, et al. Provider-Documented Anxiety in the ICU: Prevalence, Risk Factors, and Associated Patient Outcomes. J Intensive Care Med 2021; 36:1424.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McKinley S, Madronio C. Validity of the Faces Anxiety Scale for the assessment of state anxiety in intensive care patients not receiving mechanical ventilation. J Psychosom Res 2008; 64:503.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McKinley S, Coote K, Stein-Parbury J. Development and testing of a Faces Scale for the assessment of anxiety in critically ill patients. J Adv Nurs 2003; 41:73.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Griffiths J, Hatch RA, Bishop J, et al. An exploration of social and economic outcome and associated health-related quality of life after critical illness in general intensive care unit survivors: a 12-month follow-up study. Crit Care 2013; 17:R100.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Devlin JW, Skrobik Y, Gélinas C, et al. Clinical Practice Guidelines for the Prevention and Management of Pain, Agitation/Sedation, Delirium, Immobility, and Sleep Disruption in Adult Patients in the ICU. Crit Care Med 2018; 46:e825.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Milbrandt EB, Deppen S, Harrison PL, et al. Costs associated with delirium in mechanically ventilated patients. Crit Care Med 2004; 32:955.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McNicoll L, Pisani MA, Zhang Y, et al. Delirium in the intensive care unit: occurrence and clinical course in older patients. J Am Geriatr Soc 2003; 51:591.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barr J, Fraser GL, Puntillo K, et al. Clinical practice guidelines for the management of pain, agitation, and delirium in adult patients in the intensive care unit. Crit Care Med 2013; 41:263.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ely EW, Shintani A, Truman B, et al. Delirium as a predictor of mortality in mechanically ventilated patients in the intensive care unit. JAMA 2004; 291:1753.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Klein Klouwenberg PM, Zaal IJ, Spitoni C, et al. The attributable mortality of delirium in critically ill patients: prospective cohort study. BMJ 2014; 349:g6652.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mehta S, Cook D, Devlin JW, et al. Prevalence, risk factors, and outcomes of delirium in mechanically ventilated adults. Crit Care Med 2015; 43:557.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aldemir M, Ozen S, Kara IH, et al. Predisposing factors for delirium in the surgical intensive care unit. Crit Care 2001; 5:265.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ely EW, Margolin R, Francis J, et al. Evaluation of delirium in critically ill patients: validation of the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU). Crit Care Med 2001; 29:1370.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Krewulak KD, Rosgen BK, Ely EW, et al. The CAM-ICU-7 and ICDSC as measures of delirium severity in critically ill adult patients. PLoS One 2020; 15:e0242378.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fontaine DK. Nonpharmacologic management of patient distress during mechanical ventilation. Crit Care Clin 1994; 10:695.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burry LD, Cheng W, Williamson DR, et al. Pharmacological and non-pharmacological interventions to prevent delirium in critically ill patients: a systematic review and network meta-analysis. Intensive Care Med 2021; 47:943.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen TJ, Traynor V, Wang AY, et al. Comparative effectiveness of non-pharmacological interventions for preventing delirium in critically ill adults: A systematic review and network meta-analysis. Int J Nurs Stud 2022; 131:104239.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Strøm T, Martinussen T, Toft P. A protocol of no sedation for critically ill patients receiving mechanical ventilation: a randomised trial. Lancet 2010; 375:475.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Strøm T, Stylsvig M, Toft P. Long-term psychological effects of a no-sedation protocol in critically ill patients. Crit Care 2011; 15:R293.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chlan LL, Weinert CR, Heiderscheit A, et al. Effects of patient-directed music intervention on anxiety and sedative exposure in critically ill patients receiving mechanical ventilatory support: a randomized clinical trial. JAMA 2013; 309:2335.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bradt J, Dileo C. Music interventions for mechanically ventilated patients. Cochrane Database Syst Rev 2014; :CD006902.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Messika J, Martin Y, Maquigneau N, et al. A musical intervention for respiratory comfort during noninvasive ventilation in the ICU. Eur Respir J 2019; 53.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alinia-Najjar R, Bagheri-Nesami M, Shorofi SA, et al. The effect of foot reflexology massage on burn-specific pain anxiety and sleep quality and quantity of patients hospitalized in the burn intensive care unit (ICU). Burns 2020; 46:1942.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wunsch H, Kahn JM, Kramer AA, Rubenfeld GD. Use of intravenous infusion sedation among mechanically ventilated patients in the United States. Crit Care Med 2009; 37:3031.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Møller MH, Alhazzani W, Lewis K, et al. Use of dexmedetomidine for sedation in mechanically ventilated adult ICU patients: a rapid practice guideline. Intensive Care Med 2022; 48:801.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carson SS, Kress JP, Rodgers JE, et al. A randomized trial of intermittent lorazepam versus propofol with daily interruption in mechanically ventilated patients. Crit Care Med 2006; 34:1326.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lonardo NW, Mone MC, Nirula R, et al. Propofol is associated with favorable outcomes compared with benzodiazepines in ventilated intensive care unit patients. Am J Respir Crit Care Med 2014; 189:1383.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang H, Wang C, Wang Y, et al. Sedative drugs used for mechanically ventilated patients in intensive care units: a systematic review and network meta-analysis. Curr Med Res Opin 2019; 35:435.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen K, Lu Z, Xin YC, et al. Alpha-2 agonists for long-term sedation during mechanical ventilation in critically ill patients. Cochrane Database Syst Rev 2015; 1:CD010269.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jakob SM, Ruokonen E, Grounds RM, et al. Dexmedetomidine vs midazolam or propofol for sedation during prolonged mechanical ventilation: two randomized controlled trials. JAMA 2012; 307:1151.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Riker RR, Shehabi Y, Bokesch PM, et al. Dexmedetomidine vs midazolam for sedation of critically ill patients: a randomized trial. JAMA 2009; 301:489.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Adams R, Brown GT, Davidson M, et al. Efficacy of dexmedetomidine compared with midazolam for sedation in adult intensive care patients: a systematic review. Br J Anaesth 2013; 111:703.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Torbic H, Papadopoulos S, Manjourides J, Devlin JW. Impact of a protocol advocating dexmedetomidine over propofol sedation after robotic-assisted direct coronary artery bypass surgery on duration of mechanical ventilation and patient safety. Ann Pharmacother 2013; 47:441.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Klompas M, Li L, Szumita P, et al. Associations Between Different Sedatives and Ventilator-Associated Events, Length of Stay, and Mortality in Patients Who Were Mechanically Ventilated. Chest 2016; 149:1373.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Turunen H, Jakob SM, Ruokonen E, et al. Dexmedetomidine versus standard care sedation with propofol or midazolam in intensive care: an economic evaluation. Crit Care 2015; 19:67.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patanwala AE, Erstad BL. Comparison of Dexmedetomidine Versus Propofol on Hospital Costs and Length of Stay. J Intensive Care Med 2016; 31:466.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dupuis S, Brindamour D, Karzon S, et al. A systematic review of interventions to facilitate extubation in patients difficult-to-wean due to delirium, agitation, or anxiety and a meta-analysis of the effect of dexmedetomidine. Can J Anaesth 2019; 66:318.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lewis K, Alshamsi F, Carayannopoulos KL, et al. Dexmedetomidine vs other sedatives in critically ill mechanically ventilated adults: a systematic review and meta-analysis of randomized trials. Intensive Care Med 2022; 48:811.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hughes CG, Mailloux PT, Devlin JW, et al. Dexmedetomidine or Propofol for Sedation in Mechanically Ventilated Adults with Sepsis. N Engl J Med 2021; 384:1424.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reade MC, Eastwood GM, Bellomo R, et al. Effect of Dexmedetomidine Added to Standard Care on Ventilator-Free Time in Patients With Agitated Delirium: A Randomized Clinical Trial. JAMA 2016; 315:1460.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pereira JV, Sanjanwala RM, Mohammed MK, et al. Dexmedetomidine versus propofol sedation in reducing delirium among older adults in the ICU: A systematic review and meta-analysis. Eur J Anaesthesiol 2020; 37:121.
          </a>
         </li>
         <li class="breakAll">
          Alpha 2 Agonists for Sedation to Produce Better Outcomes From Critical Illness (A2B Trial). http://www.clinicaltrials.gov/ct2/show/NCT03653832 (Accessed on May 31, 2022).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pandharipande PP, Pun BT, Herr DL, et al. Effect of sedation with dexmedetomidine vs lorazepam on acute brain dysfunction in mechanically ventilated patients: the MENDS randomized controlled trial. JAMA 2007; 298:2644.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ji F, Li Z, Nguyen H, et al. Perioperative dexmedetomidine improves outcomes of cardiac surgery. Circulation 2013; 127:1576.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ji F, Li Z, Young N, et al. Perioperative dexmedetomidine improves mortality in patients undergoing coronary artery bypass surgery. J Cardiothorac Vasc Anesth 2014; 28:267.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           MacLaren R, Preslaski CR, Mueller SW, et al. A randomized, double-blind pilot study of dexmedetomidine versus midazolam for intensive care unit sedation: patient recall of their experiences and short-term psychological outcomes. J Intensive Care Med 2015; 30:167.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zaal IJ, Devlin JW, Peelen LM, Slooter AJ. A systematic review of risk factors for delirium in the ICU. Crit Care Med 2015; 43:40.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Serafim RB, Bozza FA, Soares M, et al. Pharmacologic prevention and treatment of delirium in intensive care patients: A systematic review. J Crit Care 2015; 30:799.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shehabi Y, Howe BD, Bellomo R, et al. Early Sedation with Dexmedetomidine in Critically Ill Patients. N Engl J Med 2019; 380:2506.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Venn RM, Bradshaw CJ, Spencer R, et al. Preliminary UK experience of dexmedetomidine, a novel agent for postoperative sedation in the intensive care unit. Anaesthesia 1999; 54:1136.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mueller SW, Preslaski CR, Kiser TH, et al. A randomized, double-blind, placebo-controlled dose range study of dexmedetomidine as adjunctive therapy for alcohol withdrawal. Crit Care Med 2014; 42:1131.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Polintan ETT, Danganan LML, Cruz NS, et al. Adjunctive Dexmedetomidine in Alcohol Withdrawal Syndrome: A Systematic Review and Meta-analysis of Retrospective Cohort Studies and Randomized Controlled Trials. Ann Pharmacother 2023; 57:696.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Page VJ, Ely EW, Gates S, et al. Effect of intravenous haloperidol on the duration of delirium and coma in critically ill patients (Hope-ICU): a randomised, double-blind, placebo-controlled trial. Lancet Respir Med 2013; 1:515.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pickkers P, de Keizer N, Dusseljee J, et al. Body mass index is associated with hospital mortality in critically ill patients: an observational cohort study. Crit Care Med 2013; 41:1878.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van den Boogaard M, Slooter AJC, Brüggemann RJM, et al. Effect of Haloperidol on Survival Among Critically Ill Adults With a High Risk of Delirium: The REDUCE Randomized Clinical Trial. JAMA 2018; 319:680.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Girard TD, Exline MC, Carson SS, et al. Haloperidol and Ziprasidone for Treatment of Delirium in Critical Illness. N Engl J Med 2018; 379:2506.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Andersen-Ranberg NC, Poulsen LM, Perner A, et al. Haloperidol for the Treatment of Delirium in ICU Patients. N Engl J Med 2022; 387:2425.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Devlin JW, Roberts RJ, Fong JJ, et al. Efficacy and safety of quetiapine in critically ill patients with delirium: a prospective, multicenter, randomized, double-blind, placebo-controlled pilot study. Crit Care Med 2010; 38:419.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Seemüller F, Volkmer E, Vogel T, et al. Quetiapine as treatment for delirium during weaning from ventilation: a case report. J Clin Psychopharmacol 2007; 27:526.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Skrobik YK, Bergeron N, Dumont M, Gottfried SB. Olanzapine vs haloperidol: treating delirium in a critical care setting. Intensive Care Med 2004; 30:444.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Han CS, Kim YK. A double-blind trial of risperidone and haloperidol for the treatment of delirium. Psychosomatics 2004; 45:297.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Assadoon MS, Kovacevic MP, Dube KM, et al. Evaluation of Atypical Antipsychotics for the Facilitation of Weaning Sedation in Mechanically Ventilated Critically Ill Patients. J Intensive Care Med 2024; 39:52.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Umar Z, Haseeb Ul Rasool M, Muhammad S, et al. Phenobarbital and Alcohol Withdrawal Syndrome: A Systematic Review and Meta-Analysis. Cureus 2023; 15:e33695.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Richman PS, Baram D, Varela M, Glass PS. Sedation during mechanical ventilation: a trial of benzodiazepine and opiate in combination. Crit Care Med 2006; 34:1395.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wittbrodt ET. The ideal sedation assessment tool: an elusive instrument. Crit Care Med 1999; 27:1384.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Devlin JW, Boleski G, Mlynarek M, et al. Motor Activity Assessment Scale: a valid and reliable sedation scale for use with mechanically ventilated patients in an adult surgical intensive care unit. Crit Care Med 1999; 27:1271.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Riker RR, Picard JT, Fraser GL. Prospective evaluation of the Sedation-Agitation Scale for adult critically ill patients. Crit Care Med 1999; 27:1325.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weinert C, McFarland L. The state of intubated ICU patients: development of a two-dimensional sedation rating scale for critically ill adults. Chest 2004; 126:1883.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sessler CN, Gosnell MS, Grap MJ, et al. The Richmond Agitation-Sedation Scale: validity and reliability in adult intensive care unit patients. Am J Respir Crit Care Med 2002; 166:1338.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ely EW, Truman B, Shintani A, et al. Monitoring sedation status over time in ICU patients: reliability and validity of the Richmond Agitation-Sedation Scale (RASS). JAMA 2003; 289:2983.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bizek KS. Optimizing sedation in critically ill, mechanically ventilated patients. Crit Care Nurs Clin North Am 1995; 7:315.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ambuel B, Hamlett KW, Marx CM, Blumer JL. Assessing distress in pediatric intensive care environments: the COMFORT scale. J Pediatr Psychol 1992; 17:95.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Olleveant N, Humphris G, Roe B. A reliability study of the modified new Sheffield Sedation Scale. Nurs Crit Care 1998; 3:83.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ramsay MA, Savege TM, Simpson BR, Goodwin R. Controlled sedation with alphaxalone-alphadolone. Br Med J 1974; 2:656.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee H, Ryu K, Sohn Y, et al. Impact on Patient Outcomes of Pharmacist Participation in Multidisciplinary Critical Care Teams: A Systematic Review and Meta-Analysis. Crit Care Med 2019; 47:1243.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arredondo E, Udeani G, Horseman M, et al. Role of Clinical Pharmacists in Intensive Care Units. Cureus 2021; 13:e17929.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kollef MH, Levy NT, Ahrens TS, et al. The use of continuous i.v. sedation is associated with prolongation of mechanical ventilation. Chest 1998; 114:541.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shehabi Y, Chan L, Kadiman S, et al. Sedation depth and long-term mortality in mechanically ventilated critically ill adults: a prospective longitudinal multicentre cohort study. Intensive Care Med 2013; 39:910.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shehabi Y, Bellomo R, Reade MC, et al. Early intensive care sedation predicts long-term mortality in ventilated critically ill patients. Am J Respir Crit Care Med 2012; 186:724.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mehta S, Burry L, Cook D, et al. Daily sedation interruption in mechanically ventilated critically ill patients cared for with a sedation protocol: a randomized controlled trial. JAMA 2012; 308:1985.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Olsen HT, Nedergaard HK, Strøm T, et al. Nonsedation or Light Sedation in Critically Ill, Mechanically Ventilated Patients. N Engl J Med 2020; 382:1103.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kress JP, Pohlman AS, O'Connor MF, Hall JB. Daily interruption of sedative infusions in critically ill patients undergoing mechanical ventilation. N Engl J Med 2000; 342:1471.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schweickert WD, Gehlbach BK, Pohlman AS, et al. Daily interruption of sedative infusions and complications of critical illness in mechanically ventilated patients. Crit Care Med 2004; 32:1272.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Balas MC, Vasilevskis EE, Olsen KM, et al. Effectiveness and safety of the awakening and breathing coordination, delirium monitoring/management, and early exercise/mobility bundle. Crit Care Med 2014; 42:1024.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brook AD, Ahrens TS, Schaiff R, et al. Effect of a nursing-implemented sedation protocol on the duration of mechanical ventilation. Crit Care Med 1999; 27:2609.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Wit M, Gennings C, Jenvey WI, Epstein SK. Randomized trial comparing daily interruption of sedation and nursing-implemented sedation algorithm in medical intensive care unit patients. Crit Care 2008; 12:R70.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nassar Junior AP, Park M. Daily sedative interruption versus intermittent sedation in mechanically ventilated critically ill patients: a randomized trial. Ann Intensive Care 2014; 4:14.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Girard TD, Kress JP, Fuchs BD, et al. Efficacy and safety of a paired sedation and ventilator weaning protocol for mechanically ventilated patients in intensive care (Awakening and Breathing Controlled trial): a randomised controlled trial. Lancet 2008; 371:126.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jackson JC, Girard TD, Gordon SM, et al. Long-term cognitive and psychological outcomes in the awakening and breathing controlled trial. Am J Respir Crit Care Med 2010; 182:183.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burry L, Rose L, McCullagh IJ, et al. Daily sedation interruption versus no daily sedation interruption for critically ill adult patients requiring invasive mechanical ventilation. Cochrane Database Syst Rev 2014; :CD009176.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Minhas MA, Velasquez AG, Kaul A, et al. Effect of Protocolized Sedation on Clinical Outcomes in Mechanically Ventilated Intensive Care Unit Patients: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Mayo Clin Proc 2015; 90:613.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Devlin JW, Tanios MA, Epstein SK. Intensive care unit sedation: waking up clinicians to the gap between research and practice. Crit Care Med 2006; 34:556.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mehta S, Burry L, Fischer S, et al. Canadian survey of the use of sedatives, analgesics, and neuromuscular blocking agents in critically ill patients. Crit Care Med 2006; 34:374.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kress JP, Gehlbach B, Lacy M, et al. The long-term psychological effects of daily sedative interruption on critically ill patients. Am J Respir Crit Care Med 2003; 168:1457.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kress JP, Vinayak AG, Levitt J, et al. Daily sedative interruption in mechanically ventilated patients at risk for coronary artery disease. Crit Care Med 2007; 35:365.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aitken LM, Bucknall T, Kent B, et al. Protocol-directed sedation versus non-protocol-directed sedation to reduce duration of mechanical ventilation in mechanically ventilated intensive care patients. Cochrane Database Syst Rev 2015; 1:CD009771.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Collinsworth AW, Priest EL, Campbell CR, et al. A Review of Multifaceted Care Approaches for the Prevention and Mitigation of Delirium in Intensive Care Units. J Intensive Care Med 2016; 31:127.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kher S, Roberts RJ, Garpestad E, et al. Development, implementation, and evaluation of an institutional daily awakening and spontaneous breathing trial protocol: a quality improvement project. J Intensive Care Med 2013; 28:189.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hager DN, Dinglas VD, Subhas S, et al. Reducing deep sedation and delirium in acute lung injury patients: a quality improvement project. Crit Care Med 2013; 41:1435.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Groth CM, Droege CA, Connor KA, et al. Multicenter Retrospective Review of Ketamine Use in the ICU. Crit Care Explor 2022; 4:e0633.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pendleton KM, Stephenson LE, Goeden N, et al. Ketamine Infusion for Sedation and Analgesia during Mechanical Ventilation in the ICU: A Multicenter Evaluation. Crit Care Res Pract 2022; 2022:9853344.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chan K, Burry LD, Tse C, et al. Impact of Ketamine on Analgosedative Consumption in Critically Ill Patients: A Systematic Review and Meta-Analysis. Ann Pharmacother 2022; 56:1139.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patanwala AE, Martin JR, Erstad BL. Ketamine for Analgosedation in the Intensive Care Unit: A Systematic Review. J Intensive Care Med 2017; 32:387.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kundra P, Velayudhan S, Krishnamachari S, Gupta SL. Oral ketamine and dexmedetomidine in adults' burns wound dressing--A randomized double blind cross over study. Burns 2013; 39:1150.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Norambuena C, Yañez J, Flores V, et al. Oral ketamine and midazolam for pediatric burn patients: a prospective, randomized, double-blind study. J Pediatr Surg 2013; 48:629.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cammarano WB, Pittet JF, Weitz S, et al. Acute withdrawal syndrome related to the administration of analgesic and sedative medications in adult intensive care unit patients. Crit Care Med 1998; 26:676.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Honey BL, Benefield RJ, Miller JL, Johnson PN. Alpha2-receptor agonists for treatment and prevention of iatrogenic opioid abstinence syndrome in critically ill patients. Ann Pharmacother 2009; 43:1506.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Al-Qadheeb NS, Roberts RJ, Griffin R, et al. Impact of enteral methadone on the ability to wean off continuously infused opioids in critically ill, mechanically ventilated adults: a case-control study. Ann Pharmacother 2012; 46:1160.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maccioli GA. Dexmedetomidine to facilitate drug withdrawal. Anesthesiology 2003; 98:575.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Multz AS. Prolonged dexmedetomidine infusion as an adjunct in treating sedation-induced withdrawal. Anesth Analg 2003; 96:1054.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gagnon DJ, Riker RR, Glisic EK, et al. Transition from dexmedetomidine to enteral clonidine for ICU sedation: an observational pilot study. Pharmacotherapy 2015; 35:251.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bhatt K, Thompson Quan A, Baumgartner L, et al. Effects of a Clonidine Taper on Dexmedetomidine Use and Withdrawal in Adult Critically Ill Patients-A Pilot Study. Crit Care Explor 2020; 2:e0245.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rajendraprasad S, Wheeler M, Wieruszewski E, et al. Clonidine use during dexmedetomidine weaning: A systematic review. World J Crit Care Med 2023; 12:18.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bolesta S, Burry L, Perreault MM, et al. International Analgesia and Sedation Weaning and Withdrawal Practices in Critically Ill Adults: The Adult Iatrogenic Withdrawal Study in the ICU. Crit Care Med 2023; 51:1502.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mesnil M, Capdevila X, Bringuier S, et al. Long-term sedation in intensive care unit: a randomized comparison between inhaled sevoflurane and intravenous propofol or midazolam. Intensive Care Med 2011; 37:933.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Beaurepaire R. Suppression of alcohol dependence using baclofen: a 2-year observational study of 100 patients. Front Psychiatry 2012; 3:103.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liu J, Wang LN. Baclofen for alcohol withdrawal. Cochrane Database Syst Rev 2019; 2019.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vourc'h M, Garret C, Gacouin A, et al. Effect of High-Dose Baclofen on Agitation-Related Events Among Patients With Unhealthy Alcohol Use Receiving Mechanical Ventilation: A Randomized Clinical Trial. JAMA 2021; 325:732.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 1606 Version 55.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8000919" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Improving patient tolerance of mechanical ventilation. Challenges ahead.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8092155" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Effect of analgesic treatment on the physiological consequences of acute pain.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33034254" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Provider-Documented Anxiety in the ICU: Prevalence, Risk Factors, and Associated Patient Outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18440403" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Validity of the Faces Anxiety Scale for the assessment of state anxiety in intensive care patients not receiving mechanical ventilation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12519290" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Development and testing of a Faces Scale for the assessment of anxiety in critically ill patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23714692" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : An exploration of social and economic outcome and associated health-related quality of life after critical illness in general intensive care unit survivors: a 12-month follow-up study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30113379" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Clinical Practice Guidelines for the Prevention and Management of Pain, Agitation/Sedation, Delirium, Immobility, and Sleep Disruption in Adult Patients in the ICU.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15071384" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Costs associated with delirium in mechanically ventilated patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12752832" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Delirium in the intensive care unit: occurrence and clinical course in older patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23269131" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Clinical practice guidelines for the management of pain, agitation, and delirium in adult patients in the intensive care unit.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15082703" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Delirium as a predictor of mortality in mechanically ventilated patients in the intensive care unit.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25422275" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : The attributable mortality of delirium in critically ill patients: prospective cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25493968" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Prevalence, risk factors, and outcomes of delirium in mechanically ventilated adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11737901" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Predisposing factors for delirium in the surgical intensive care unit.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11445689" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Evaluation of delirium in critically ill patients: validation of the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33196655" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : The CAM-ICU-7 and ICDSC as measures of delirium severity in critically ill adult patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8000922" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Nonpharmacologic management of patient distress during mechanical ventilation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34379152" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Pharmacological and non-pharmacological interventions to prevent delirium in critically ill patients: a systematic review and network meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35468538" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Comparative effectiveness of non-pharmacological interventions for preventing delirium in critically ill adults: A systematic review and network meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20116842" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : A protocol of no sedation for critically ill patients receiving mechanical ventilation: a randomised trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22166673" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Long-term psychological effects of a no-sedation protocol in critically ill patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23689789" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Effects of patient-directed music intervention on anxiety and sedative exposure in critically ill patients receiving mechanical ventilatory support: a randomized clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25490233" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Music interventions for mechanically ventilated patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30578396" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : A musical intervention for respiratory comfort during noninvasive ventilation in the ICU.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32873443" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : The effect of foot reflexology massage on burn-specific pain anxiety and sleep quality and quantity of patients hospitalized in the burn intensive care unit (ICU).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19633543" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Use of intravenous infusion sedation among mechanically ventilated patients in the United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35587274" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Use of dexmedetomidine for sedation in mechanically ventilated adult ICU patients: a rapid practice guideline.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16540958" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : A randomized trial of intermittent lorazepam versus propofol with daily interruption in mechanically ventilated patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24720509" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Propofol is associated with favorable outcomes compared with benzodiazepines in ventilated intensive care unit patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30086671" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Sedative drugs used for mechanically ventilated patients in intensive care units: a systematic review and network meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25879090" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Alpha-2 agonists for long-term sedation during mechanical ventilation in critically ill patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22436955" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Dexmedetomidine vs midazolam or propofol for sedation during prolonged mechanical ventilation: two randomized controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19188334" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Dexmedetomidine vs midazolam for sedation of critically ill patients: a randomized trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23748199" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Efficacy of dexmedetomidine compared with midazolam for sedation in adult intensive care patients: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23535816" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Impact of a protocol advocating dexmedetomidine over propofol sedation after robotic-assisted direct coronary artery bypass surgery on duration of mechanical ventilation and patient safety.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26501514" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Associations Between Different Sedatives and Ventilator-Associated Events, Length of Stay, and Mortality in Patients Who Were Mechanically Ventilated.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25887576" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Dexmedetomidine versus standard care sedation with propofol or midazolam in intensive care: an economic evaluation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25061063" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Comparison of Dexmedetomidine Versus Propofol on Hospital Costs and Length of Stay.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30674004" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : A systematic review of interventions to facilitate extubation in patients difficult-to-wean due to delirium, agitation, or anxiety and a meta-analysis of the effect of dexmedetomidine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35648198" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Dexmedetomidine vs other sedatives in critically ill mechanically ventilated adults: a systematic review and meta-analysis of randomized trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33528922" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Dexmedetomidine or Propofol for Sedation in Mechanically Ventilated Adults with Sepsis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26975647" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Effect of Dexmedetomidine Added to Standard Care on Ventilator-Free Time in Patients With Agitated Delirium: A Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31860605" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Dexmedetomidine versus propofol sedation in reducing delirium among older adults in the ICU: A systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31860605" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Dexmedetomidine versus propofol sedation in reducing delirium among older adults in the ICU: A systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18073360" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Effect of sedation with dexmedetomidine vs lorazepam on acute brain dysfunction in mechanically ventilated patients: the MENDS randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23513068" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Perioperative dexmedetomidine improves outcomes of cardiac surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24182835" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Perioperative dexmedetomidine improves mortality in patients undergoing coronary artery bypass surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24227448" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : A randomized, double-blind pilot study of dexmedetomidine versus midazolam for intensive care unit sedation: patient recall of their experiences and short-term psychological outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25251759" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : A systematic review of risk factors for delirium in the ICU.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25957498" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Pharmacologic prevention and treatment of delirium in intensive care patients: A systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31112380" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Early Sedation with Dexmedetomidine in Critically Ill Patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10594409" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Preliminary UK experience of dexmedetomidine, a novel agent for postoperative sedation in the intensive care unit.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24351375" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : A randomized, double-blind, placebo-controlled dose range study of dexmedetomidine as adjunctive therapy for alcohol withdrawal.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36258676" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Adjunctive Dexmedetomidine in Alcohol Withdrawal Syndrome: A Systematic Review and Meta-analysis of Retrospective Cohort Studies and Randomized Controlled Trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24461612" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Effect of intravenous haloperidol on the duration of delirium and coma in critically ill patients (Hope-ICU): a randomised, double-blind, placebo-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23685638" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Body mass index is associated with hospital mortality in critically ill patients: an observational cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29466591" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Effect of Haloperidol on Survival Among Critically Ill Adults With a High Risk of Delirium: The REDUCE Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30346242" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Haloperidol and Ziprasidone for Treatment of Delirium in Critical Illness.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36286254" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Haloperidol for the Treatment of Delirium in ICU Patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19915454" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Efficacy and safety of quetiapine in critically ill patients with delirium: a prospective, multicenter, randomized, double-blind, placebo-controlled pilot study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17873696" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Quetiapine as treatment for delirium during weaning from ventilation: a case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14685663" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Olanzapine vs haloperidol: treating delirium in a critical care setting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15232043" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : A double-blind trial of risperidone and haloperidol for the treatment of delirium.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37431208" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Evaluation of Atypical Antipsychotics for the Facilitation of Weaning Sedation in Mechanically Ventilated Critically Ill Patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36788902" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Phenobarbital and Alcohol Withdrawal Syndrome: A Systematic Review and Meta-Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16540957" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Sedation during mechanical ventilation: a trial of benzodiazepine and opiate in combination.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10446838" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : The ideal sedation assessment tool: an elusive instrument.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10446819" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Motor Activity Assessment Scale: a valid and reliable sedation scale for use with mechanically ventilated patients in an adult surgical intensive care unit.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10446827" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Prospective evaluation of the Sedation-Agitation Scale for adult critically ill patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15596688" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : The state of intubated ICU patients: development of a two-dimensional sedation rating scale for critically ill adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12421743" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : The Richmond Agitation-Sedation Scale: validity and reliability in adult intensive care unit patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12799407" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Monitoring sedation status over time in ICU patients: reliability and validity of the Richmond Agitation-Sedation Scale (RASS).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7619374" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Optimizing sedation in critically ill, mechanically ventilated patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1545324" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Assessing distress in pediatric intensive care environments: the COMFORT scale.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9883167" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : A reliability study of the modified new Sheffield Sedation Scale.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4835444" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Controlled sedation with alphaxalone-alphadolone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31135496" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Impact on Patient Outcomes of Pharmacist Participation in Multidisciplinary Critical Care Teams: A Systematic Review and Meta-Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34660121" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Role of Clinical Pharmacists in Intensive Care Units.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9726743" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : The use of continuous i.v. sedation is associated with prolongation of mechanical ventilation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23344834" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Sedation depth and long-term mortality in mechanically ventilated critically ill adults: a prospective longitudinal multicentre cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22859526" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Early intensive care sedation predicts long-term mortality in ventilated critically ill patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23180503" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Daily sedation interruption in mechanically ventilated critically ill patients cared for with a sedation protocol: a randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32068366" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Nonsedation or Light Sedation in Critically Ill, Mechanically Ventilated Patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10816184" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Daily interruption of sedative infusions in critically ill patients undergoing mechanical ventilation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15187505" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Daily interruption of sedative infusions and complications of critical illness in mechanically ventilated patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24394627" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Effectiveness and safety of the awakening and breathing coordination, delirium monitoring/management, and early exercise/mobility bundle.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10628598" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Effect of a nursing-implemented sedation protocol on the duration of mechanical ventilation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18492267" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Randomized trial comparing daily interruption of sedation and nursing-implemented sedation algorithm in medical intensive care unit patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24900938" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Daily sedative interruption versus intermittent sedation in mechanically ventilated critically ill patients: a randomized trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18191684" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Efficacy and safety of a paired sedation and ventilator weaning protocol for mechanically ventilated patients in intensive care (Awakening and Breathing Controlled trial): a randomised controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20299535" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Long-term cognitive and psychological outcomes in the awakening and breathing controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25005604" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Daily sedation interruption versus no daily sedation interruption for critically ill adult patients requiring invasive mechanical ventilation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25865475" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Effect of Protocolized Sedation on Clinical Outcomes in Mechanically Ventilated Intensive Care Unit Patients: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16424748" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Intensive care unit sedation: waking up clinicians to the gap between research and practice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16424717" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Canadian survey of the use of sedatives, analgesics, and neuromuscular blocking agents in critically ill patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14525802" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : The long-term psychological effects of daily sedative interruption on critically ill patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17205005" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Daily sedative interruption in mechanically ventilated patients at risk for coronary artery disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25562750" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Protocol-directed sedation versus non-protocol-directed sedation to reduce duration of mechanical ventilation in mechanically ventilated intensive care patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25348864" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : A Review of Multifaceted Care Approaches for the Prevention and Mitigation of Delirium in Intensive Care Units.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22596087" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Development, implementation, and evaluation of an institutional daily awakening and spontaneous breathing trial protocol: a quality improvement project.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23507716" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Reducing deep sedation and delirium in acute lung injury patients: a quality improvement project.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35187497" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Multicenter Retrospective Review of Ketamine Use in the ICU.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36504505" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Ketamine Infusion for Sedation and Analgesia during Mechanical Ventilation in the ICU: A Multicenter Evaluation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35081769" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Impact of Ketamine on Analgosedative Consumption in Critically Ill Patients: A Systematic Review and Meta-Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26647407" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Ketamine for Analgosedation in the Intensive Care Unit: A Systematic Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23623339" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Oral ketamine and dexmedetomidine in adults' burns wound dressing--A randomized double blind cross over study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23480923" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Oral ketamine and midazolam for pediatric burn patients: a prospective, randomized, double-blind study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9559604" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Acute withdrawal syndrome related to the administration of analgesic and sedative medications in adult intensive care unit patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19690220" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Alpha2-receptor agonists for treatment and prevention of iatrogenic opioid abstinence syndrome in critically ill patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22872749" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : Impact of enteral methadone on the ability to wean off continuously infused opioids in critically ill, mechanically ventilated adults: a case-control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12552220" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : Dexmedetomidine to facilitate drug withdrawal.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12651659" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : Prolonged dexmedetomidine infusion as an adjunct in treating sedation-induced withdrawal.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25809176" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : Transition from dexmedetomidine to enteral clonidine for ICU sedation: an observational pilot study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33163969" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : Effects of a Clonidine Taper on Dexmedetomidine Use and Withdrawal in Adult Critically Ill Patients-A Pilot Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36683967" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : Clonidine use during dexmedetomidine weaning: A systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37283558" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : International Analgesia and Sedation Weaning and Withdrawal Practices in Critically Ill Adults: The Adult Iatrogenic Withdrawal Study in the ICU.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21445642" id="rid116" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          117 : Long-term sedation in intensive care unit: a randomized comparison between inhaled sevoflurane and intravenous propofol or midazolam.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23316172" id="rid117" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          118 : Suppression of alcohol dependence using baclofen: a 2-year observational study of 100 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31689723" id="rid118" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          119 : Baclofen for alcohol withdrawal.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33620407" id="rid119" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          120 : Effect of High-Dose Baclofen on Agitation-Related Events Among Patients With Unhealthy Alcohol Use Receiving Mechanical Ventilation: A Randomized Clinical Trial.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
